https://www.gensight-biologics.com/fr/2018/06/04/bio-international-convention-boston-ma-us/ 2026-07-15T19:56:55+00:00 https://www.gensight-biologics.com/fr/2018/07/09/iscas-2018-florence-italie/ 2026-07-15T19:56:56+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/gensight-certificate.jpg https://www.gensight-biologics.com/wp-content/uploads/2018/04/gensight-certificate-500x351.jpg https://www.gensight-biologics.com/fr/2018/10/02/2nd-annual-gene-therapy-for-rare-disorders-europe-london-uk/ 2026-07-15T19:56:59+00:00 https://www.gensight-biologics.com/fr/2018/10/08/salon-actionaria-2018-paris-france/ 2026-07-15T19:57:00+00:00 https://www.gensight-biologics.com/fr/2018/11/06/world-orphan-drug-congress-europe-barcelona-spain/ 2026-07-15T19:57:01+00:00 https://www.gensight-biologics.com/fr/2018/12/07/37th-annual-j-p-morgan-healthcare-conference-san-francisco-ca-usa/ 2026-07-15T19:57:02+00:00 https://www.gensight-biologics.com/fr/2018/12/07/oddo-bhf-forum-lyon-france/ 2026-07-15T19:57:03+00:00 https://www.gensight-biologics.com/fr/2018/12/07/45th-nanos-annual-meeting-las-vegas-nevada-us/ 2026-07-15T19:57:04+00:00 https://www.gensight-biologics.com/fr/2019/01/23/bioeurope-spring-vienne-autriche/ 2026-07-15T19:57:05+00:00 https://www.gensight-biologics.com/fr/2019/03/01/9th-euretina-winter-meeting-prague-republique-tcheque/ 2026-07-15T19:57:08+00:00 https://www.gensight-biologics.com/fr/2019/05/22/presentation-investisseurs-des-resultats-cliniques-de-phase-3-de-gs010-pour-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber-nohl-new-york/ 2026-07-15T19:57:13+00:00 https://www.gensight-biologics.com/fr/2019/06/13/congres-soe-2019-european-society-of-ophthalmology-nice-france/ 2026-07-15T19:57:14+00:00 https://www.gensight-biologics.com/fr/2019/06/03/presentation-des-recents-resultats-des-etudes-reverse-rescue-avec-gs010-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber/ 2026-07-15T19:57:14+00:00 https://www.gensight-biologics.com/fr/2019/06/17/14eme-congres-eunos-porto-portugal/ 2026-07-15T19:57:14+00:00 https://www.gensight-biologics.com/fr/2019/07/25/congres-annuel-asrs-2019-chicago-il-us/ 2026-07-15T19:57:17+00:00 https://www.gensight-biologics.com/fr/2019/08/05/euretina-2019-paris-france/ 2026-07-15T19:57:17+00:00 https://www.gensight-biologics.com/fr/2019/09/19/1ere-edition-investir-day-paris-france/ 2026-07-15T19:57:18+00:00 https://www.gensight-biologics.com/fr/2019/10/14/rd-annual-gene-therapy-for-rare-disorders-europe-londres-uk/ 2026-07-15T19:57:22+00:00 https://www.gensight-biologics.com/fr/2019/10/14/esgct-27th-annual-congress-barcelona-spain/ 2026-07-15T19:57:22+00:00 https://www.gensight-biologics.com/fr/2020/02/04/2020-cell-gene-meeting-on-the-mediterranean-barcelone-espagne/ 2026-07-15T19:57:27+00:00 https://www.gensight-biologics.com/fr/2020/04/09/h-c-wainwright-global-life-sciences-conference-londres-uk-annule/ 2026-07-15T19:57:30+00:00 https://www.gensight-biologics.com/fr/2020/04/22/2020-aan-annual-meeting-toronto-canada-annule-a-cause-du-covid-19/ 2026-07-15T19:57:31+00:00 https://www.gensight-biologics.com/fr/2020/04/29/asgct-23rd-annual-meeting-boston-ma-usa-format-virtuel/ 2026-07-15T19:57:32+00:00 https://www.gensight-biologics.com/fr/2020/05/19/2020-arvo-annual-meeting-baltimore-md-us-annule/ 2026-07-15T19:57:33+00:00 https://www.gensight-biologics.com/fr/2020/05/19/bio-2020-san-diego-ca-us-format-virtuel/ 2026-07-15T19:57:34+00:00 https://www.gensight-biologics.com/fr/2020/06/24/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl/ 2026-07-15T19:57:34+00:00 https://www.gensight-biologics.com/fr/2020/07/02/e-meeting-dedie-aux-investisseurs-particuliers-sur-les-recents-developpements-et-prochaines-etapes-de-lumevoq-dans-le-traitement-de-la-nohl/ 2026-07-15T19:57:34+00:00 https://www.gensight-biologics.com/fr/2020/07/30/38eme-congres-scientifique-annuel-asrs-2020-format-virtuel/ 2026-07-15T19:57:36+00:00 https://www.gensight-biologics.com/fr/2020/07/30/umdf-power-surge-2020-format-virtuel/ 2026-07-15T19:57:38+00:00 https://www.gensight-biologics.com/fr/2020/09/14/h-c-wainwright-22nd-annual-global-investment-conference-conference-virtuelle/ 2026-07-15T19:57:39+00:00 https://www.gensight-biologics.com/fr/2020/10/01/chardan-4th-annual-genetic-medicines-conference-format-virtuel/ 2026-07-15T19:57:40+00:00 https://www.gensight-biologics.com/fr/2020/10/01/ophthalmology-futures-retina-forum-virtuel/ 2026-07-15T19:57:40+00:00 https://www.gensight-biologics.com/fr/2020/10/01/healthtech-innovation-days-htid-paris-france-format-virtuel/ 2026-07-15T19:57:40+00:00 https://www.gensight-biologics.com/fr/2020/10/01/euretina-2020-format-virtuel/ 2026-07-15T19:57:42+00:00 https://www.gensight-biologics.com/fr/2020/10/05/cell-gene-meeting-on-the-mesa-format-virtuel/ 2026-07-15T19:57:42+00:00 https://www.gensight-biologics.com/fr/2020/10/19/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel/ 2026-07-15T19:57:43+00:00 https://www.gensight-biologics.com/fr/2020/11/02/eyecelerator-2020-conference-virtuelle/ 2026-07-15T19:57:46+00:00 https://www.gensight-biologics.com/fr/2020/11/12/american-academy-of-ophthalmology-2020-virtuel/ 2026-07-15T19:57:47+00:00 https://www.gensight-biologics.com/fr/2020/11/13/bryan-garnier-european-healthcare-conference-2020-format-virtuel/ 2026-07-15T19:57:47+00:00 https://www.gensight-biologics.com/fr/2021/01/07/6447/ 2026-07-15T19:57:48+00:00 https://www.gensight-biologics.com/fr/2021/01/07/47th-nanos-annual-meeting-virtual-meeting/ 2026-07-15T19:57:48+00:00 https://www.gensight-biologics.com/fr/2021/02/05/44th-annual-macula-society-meeting-format-virtuel/ 2026-07-15T19:57:52+00:00 https://www.gensight-biologics.com/fr/2021/02/12/ois-gene-therapy-innovation-showcase-format-virtuel/ 2026-07-15T19:57:52+00:00 https://www.gensight-biologics.com/fr/2021/02/12/4eme-congres-annuel-gene-therapy-for-rare-disorders-format-virtuel/ 2026-07-15T19:57:52+00:00 https://www.gensight-biologics.com/fr/2021/03/08/ophthalmology-future-forums-asian-retina-virtual-forum-march-25-2021/ 2026-07-15T19:57:53+00:00 https://www.gensight-biologics.com/fr/2021/03/08/cell-gene-meeting-on-the-mediterranean-virtual/ 2026-07-15T19:57:53+00:00 https://www.gensight-biologics.com/fr/2021/03/08/2021-aan-annual-meeting-virtual/ 2026-07-15T19:57:54+00:00 https://www.gensight-biologics.com/fr/2021/03/15/bioeurope-spring-format-virtuel/ 2026-07-15T19:57:56+00:00 https://www.gensight-biologics.com/fr/2021/04/19/mitochondria-targeted-drug-development-summit-digital/ 2026-07-15T19:57:57+00:00 https://www.gensight-biologics.com/fr/2021/04/27/assemblee-generale-mixte-2021/ 2026-07-15T19:57:58+00:00 https://www.gensight-biologics.com/fr/2021/04/20/2021-arvo-annual-meeting-format-virtuel/ 2026-07-15T19:57:58+00:00 https://www.gensight-biologics.com/fr/2021/05/18/advanced-therapies-digital/ 2026-07-15T19:58:01+00:00 https://www.gensight-biologics.com/fr/2021/05/28/webinaire-avec-des-leaders-dopinion-sur-la-publication-dans-nature-medicine-dun-cas-de-recuperation-visuelle-apres-traitement-optogenetique-par-gs030/ 2026-07-15T19:58:02+00:00 https://www.gensight-biologics.com/fr/2021/06/08/bio-us-2021-digital/ 2026-07-15T19:58:03+00:00 https://www.gensight-biologics.com/fr/2021/06/08/clinical-operations-strategy-meeting-online-2021/ 2026-07-15T19:58:05+00:00 https://www.gensight-biologics.com/fr/2021/06/15/umdf-mitochondrial-medicine-2021-virtuel/ 2026-07-15T19:58:06+00:00 https://www.gensight-biologics.com/fr/2021/06/29/biotech-outsourcing-strategies-bos-2021-format-virtuel/ 2026-07-15T19:58:06+00:00 https://www.gensight-biologics.com/fr/2021/07/06/webcast-avec-des-leaders-dopinion-sur-les-resultats-de-letude-clinique-de-phase-iii-reflect-de-lumevoq/ 2026-07-15T19:58:07+00:00 https://www.gensight-biologics.com/fr/2021/07/06/webcast-pour-les-investisseurs-particuliers-sur-les-resultats-de-letude-clinique-de-phase-iii-reflect-de-lumevoq/ 2026-07-15T19:58:07+00:00 https://www.gensight-biologics.com/fr/2021/07/12/ois-european-innovation-showcase-virtuel/ 2026-07-15T19:58:07+00:00 https://www.gensight-biologics.com/fr/2021/09/02/congres-isgedr-2021-international-society-for-genetic-eye-diseases-retinoblastoma/ 2026-07-15T19:58:10+00:00 https://www.gensight-biologics.com/fr/2021/09/07/ophthalmology-future-forums-euro-retina-virtual-forum-september-8-2021/ 2026-07-15T19:58:11+00:00 https://www.gensight-biologics.com/fr/2021/09/02/redburn-gene-therapy-virtual-summit-2021-format-virtuel/ 2026-07-15T19:58:11+00:00 https://www.gensight-biologics.com/fr/2021/09/13/clinical-trials-in-rare-diseases-conference-2021-europe-and-usa-virtual-conference/ 2026-07-15T19:58:12+00:00 https://www.gensight-biologics.com/fr/2021/09/13/5th-annual-cell-gene-therapy-world-asia-virtual/ 2026-07-15T19:58:12+00:00 https://www.gensight-biologics.com/fr/2021/09/13/2nd-annual-gene-therapy-for-ophthalmic-disorders-virtuel/ 2026-07-15T19:58:14+00:00 https://www.gensight-biologics.com/fr/2021/09/24/54th-annual-scientific-meeting-of-the-retina-society-chicago-il-usa/ 2026-07-15T19:58:15+00:00 https://www.gensight-biologics.com/fr/2021/09/24/advanced-therapies-connect-virtuel/ 2026-07-15T19:58:15+00:00 https://www.gensight-biologics.com/fr/2021/10/04/healthtech-innovation-days-htid-virtuel/ 2026-07-15T19:58:15+00:00 https://www.gensight-biologics.com/fr/2021/10/05/ois-retina-innovation-summit-asrs-austin-tx-usa/ 2026-07-15T19:58:16+00:00 https://www.gensight-biologics.com/fr/2021/10/04/2021-advanced-therapies-congress-live-london-uk/ 2026-07-15T19:58:16+00:00 https://www.gensight-biologics.com/fr/2021/10/04/chardan-5th-annual-genetic-medicines-conference-virtuel/ 2026-07-15T19:58:16+00:00 https://www.gensight-biologics.com/fr/2021/10/11/2021-arm-cell-gene-meeting-on-the-mesa-carlsbad-ca-usa-virtuel-2/ 2026-07-15T19:58:19+00:00 https://www.gensight-biologics.com/fr/2021/10/06/39th-annual-scientific-meeting-of-the-american-society-of-retina-specialists-asrs-san-antonio-tx-usa/ 2026-07-15T19:58:19+00:00 https://www.gensight-biologics.com/fr/2021/10/11/28th-annual-congress-of-the-european-society-of-gene-cell-therapy-esgct-virtuel/ 2026-07-15T19:58:19+00:00 https://www.gensight-biologics.com/fr/2021/10/18/cell-uk-by-oxfords-global-london-uk-virtual/ 2026-07-15T19:58:20+00:00 https://www.gensight-biologics.com/fr/2021/10/18/bio-europe-virtuel/ 2026-07-15T19:58:20+00:00 https://www.gensight-biologics.com/fr/2021/10/11/mitochondrial-diseases-conference-2021-by-mitocon-virtuel/ 2026-07-15T19:58:20+00:00 https://www.gensight-biologics.com/fr/2018/09/12/ophthalmology-innovation-summit-aao-chicago-il/ 2026-07-17T20:34:44+00:00 https://www.gensight-biologics.com/fr/2018/06/26/ophthalmology-innovation-summit-retina-vancouver-bc-canada/ 2026-07-17T20:34:45+00:00 https://www.gensight-biologics.com/fr/2018/09/12/chardan-2nd-annual-genetic-medicines-conference-nyc-us/ 2026-07-17T20:34:45+00:00 https://www.gensight-biologics.com/fr/2018/09/12/american-academy-of-ophthalmology-chicago-il/ 2026-07-17T20:34:45+00:00 https://www.gensight-biologics.com/fr/2018/05/21/gensight-biologics-kol-evenement-12-juin-2018/ 2026-07-17T20:34:46+00:00 https://www.gensight-biologics.com/2022/11/04/gensight-biologics-secures-a-e35-million-credit-facility-from-the-european-investment-bank-to-support-the-launch-of-lumevoq-in-europe/ 2026-07-17T20:42:22+00:00 https://www.gensight-biologics.com/2022/07/20/gensight-biologics-reports-5-years-data-showing-sustained-efficacy-and-safety-following-one-time-treatment-with-lumevoq/ 2026-07-17T20:42:24+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-def.jpg https://www.gensight-biologics.com/2021/11/30/gensight-biologics-to-host-key-opinion-leader-webcast-on-outcomes-among-compassionate-use-patients-treated-bilaterally-with-lumevoq-in-the-us-2/ 2026-07-17T20:43:15+00:00 https://www.gensight-biologics.com/fr/2026/05/18/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026/ 2026-09-24T04:05:29+00:00 https://www.gensight-biologics.com/fr/2026/04/15/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2025/ 2026-09-24T04:05:30+00:00 https://www.gensight-biologics.com/fr/2026/05/11/gensight-biologics-annonce-la-publication-dune-comparaison-indirecte-ajustee-par-appariement-des-traitements-de-la-neuropathie-optique-hereditaire-de-leber/ 2026-09-24T04:05:30+00:00 https://www.gensight-biologics.com/fr/2026/04/28/lassemblee-generale-mixte-de-gensight-biologics-aura-lieu-le-19-mai-2026/ 2026-09-24T04:05:30+00:00 https://www.gensight-biologics.com/fr/2026/04/07/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026/ 2026-09-24T04:05:31+00:00 https://www.gensight-biologics.com/fr/2026/04/03/gensight-biologics-confirme-que-les-resultats-financiers-consolides-definitifs-de-lexercice-2025-sont-conformes-aux-estimations/ 2026-09-24T04:05:31+00:00 https://www.gensight-biologics.com/fr/2026/03/20/lhopital-national-des-15-20-et-gensight-biologics-annoncent-les-premiers-traitements-dans-le-cadre-du-programme-dautorisation-dacces-compassionnel-aac-pour-gs010-lumevoq/ 2026-09-24T04:05:32+00:00 https://www.gensight-biologics.com/fr/2026/03/27/gensight-biologics-publie-ses-resultats-financiers-consolides-estimes-pour-lannee-2025/ 2026-09-24T04:05:32+00:00 https://www.gensight-biologics.com/fr/2026/03/17/gensight-biologics-annonce-le-reglement-livraison-de-sa-levee-de-fonds-de-pres-de-17-millions-deuros/ 2026-09-24T04:05:32+00:00 https://www.gensight-biologics.com/fr/2026/03/09/gensight-biologics-fait-le-point-sur-les-programmes-dacces-precoce-de-gs010-lumevoq-et-sur-letude-revise-en-cours/ 2026-09-24T04:05:33+00:00 https://www.gensight-biologics.com/fr/2026/03/10/gensight-biologics-realise-une-levee-de-fonds-dun-montant-de-pres-de-17-million-deuros/ 2026-09-24T04:05:33+00:00 https://www.gensight-biologics.com/fr/2026/02/18/gensight-biologics-renforce-son-equipe-reglementaire-aux-etats-unis-et-en-europe-avec-deux-nominations-au-sein-de-sa-direction/ 2026-09-24T04:05:34+00:00 https://www.gensight-biologics.com/fr/2026/02/10/lhopital-national-des-15-20-et-gensight-biologics-annoncent-le-traitement-du-premier-patient-dans-le-cadre-de-letude-revise-de-gs010-lumevoq/ 2026-09-24T04:05:34+00:00 https://www.gensight-biologics.com/fr/2026/01/28/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026/ 2026-09-24T04:05:34+00:00 https://www.gensight-biologics.com/fr/2026/01/08/gensight-biologics-publie-sa-situation-de-tresorerie-au-31-decembre-2025-et-fait-un-point-sur-son-activite/ 2026-09-24T04:05:35+00:00 https://www.gensight-biologics.com/fr/2026/01/07/gensight-biologics-annonce-le-reglement-livraison-de-son-financement-de-pres-de-29-millions-deuros/ 2026-09-24T04:05:35+00:00 https://www.gensight-biologics.com/fr/2025/12/29/gensight-biologics-realise-une-levee-de-fonds-dun-montant-de-pres-de-e29-millions-deuros/ 2026-09-24T04:05:36+00:00 https://www.gensight-biologics.com/fr/2025/12/22/gensight-biologics-annonce-lautorisation-reglementaire-de-traiter-des-patients-en-israel-avec-gs010-lumevoq-dans-le-cadre-dun-acces-compassionnel/ 2026-09-24T04:05:36+00:00 https://www.gensight-biologics.com/fr/2025/12/22/gensight-biologics-annonce-la-delivrance-dune-autorisation-dacces-compassionnel-aac-pour-gs010-lumevoq-en-france/ 2026-09-24T04:05:37+00:00 https://www.gensight-biologics.com/fr/2025/12/02/gensight-biologics-annonce-lapprobation-reglementaire-de-letude-dose-ranging-revise-de-gs010-lumevoq-en-france/ 2026-09-24T04:05:37+00:00 https://www.gensight-biologics.com/fr/2025/11/13/gensight-biologics-annonce-le-reglement-livraison-de-son-financement-de-pres-de-2-millions-deuros/ 2026-09-24T04:05:37+00:00 https://www.gensight-biologics.com/fr/2025/10/30/gensight-biologics-annonce-avoir-obtenu-les-autorisations-reglementaires-pour-traiter-un-patient-aux-etats-unis-avec-gs010-lumevoq-dans-le-cadre-dun-acces-compassionnel-expanded-access/ 2026-09-24T04:05:38+00:00 https://www.gensight-biologics.com/fr/2025/11/10/gensight-biologics-realise-une-levee-de-fonds-dun-montant-de-pres-de-e2-millions-deuros/ 2026-09-24T04:05:38+00:00 https://www.gensight-biologics.com/fr/2025/09/29/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2025/ 2026-09-24T04:05:39+00:00 https://www.gensight-biologics.com/fr/2025/10/07/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025/ 2026-09-24T04:05:39+00:00 https://www.gensight-biologics.com/fr/2025/10/01/gensight-biologics-annonce-le-reglement-livraison-de-son-financement-de-pres-de-37-millions-deuros/ 2026-09-24T04:05:39+00:00 https://www.gensight-biologics.com/fr/2025/09/26/gensight-biologics-realise-une-levee-de-fonds-dun-montant-de-pres-de-37-millions-deuros/ 2026-09-24T04:05:40+00:00 https://www.gensight-biologics.com/fr/2025/08/28/gensight-biologics-reporte-la-publication-de-ses-resultats-financiers-semestriels-2025/ 2026-09-24T04:05:40+00:00 https://www.gensight-biologics.com/fr/2025/07/17/gensight-biologics-annonce-un-financement-complementaire-denviron-500-000-euros-par-un-actionnaire-existant/ 2026-09-24T04:05:41+00:00 https://www.gensight-biologics.com/fr/2025/07/22/gensight-biologics-annonce-le-reglement-livraison-de-son-financement-complementaire-denviron-500-000-euros/ 2026-09-24T04:05:41+00:00 https://www.gensight-biologics.com/fr/2025/07/17/gensight-biologics-annonce-la-publication-dun-article-sur-les-facteurs-predictifs-du-resultat-visuel-final-chez-les-patients-traites-par-la-therapie-genique-lumevoq/ 2026-09-24T04:05:41+00:00 https://www.gensight-biologics.com/fr/2025/07/08/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-juin-2025/ 2026-09-24T04:05:42+00:00 https://www.gensight-biologics.com/fr/2025/07/03/gensight-biologics-annonce-le-reglement-livraison-de-son-placement-prive-de-pres-de-4-millions-deuros/ 2026-09-24T04:05:42+00:00 https://www.gensight-biologics.com/fr/2025/07/01/gensight-biologics-realise-avec-succes-un-placement-prive-dun-montant-de-pres-de-4-millions-deuros/ 2026-09-24T04:05:42+00:00 https://www.gensight-biologics.com/fr/2025/06/26/gensight-biologics-annonce-une-avancee-majeure-dans-son-nouveau-partenariat-de-fabrication-avec-catalent/ 2026-09-24T04:05:43+00:00 https://www.gensight-biologics.com/fr/2025/06/12/gensight-biologics-parvient-a-un-accord-avec-lansm-pour-louverture-du-programme-dacces-compassionnel-de-lumevoq-en-france/ 2026-09-24T04:05:43+00:00 https://www.gensight-biologics.com/fr/2025/05/13/retransmission-de-lassemblee-generale-mixte-du-13-mai-2025-a-paris/ 2026-09-24T04:05:43+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Screenshot-AGM-2025.png https://www.gensight-biologics.com/wp-content/uploads/2025/05/Screenshot-AGM-2025-500x264.png https://www.gensight-biologics.com/fr/2025/04/23/assemblee-generale-mixte-du-13-mai-2025/ 2026-09-24T04:05:44+00:00 https://www.gensight-biologics.com/fr/2025/05/13/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte-du-13-mai-2025/ 2026-09-24T04:05:44+00:00 https://www.gensight-biologics.com/fr/2025/04/07/gensight-biologics-publie-sa-situation-de-tresorerie-au-31-mars-2025-et-fait-le-point-sur-ses-activites/ 2026-09-24T04:05:45+00:00 https://www.gensight-biologics.com/fr/2025/03/19/gensight-biologics-confirme-que-les-resultats-financiers-consolides-definitifs-de-lexercice-2024-sont-conformes-aux-estimations/ 2026-09-24T04:05:45+00:00 https://www.gensight-biologics.com/fr/2025/04/08/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2024/ 2026-09-24T04:05:45+00:00 https://www.gensight-biologics.com/fr/2025/03/17/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2025-du-nanos/ 2026-09-24T04:05:46+00:00 https://www.gensight-biologics.com/fr/2025/03/07/gensight-biologics-annonce-un-financement-dun-montant-denviron-09-million-deuros-aupres-dinvestisseurs-existants/ 2026-09-24T04:05:46+00:00 https://www.gensight-biologics.com/fr/2025/02/27/gensight-biologics-publie-ses-resultats-financiers-consolides-estimes-pour-lannee-2024/ 2026-09-24T04:05:46+00:00 https://www.gensight-biologics.com/fr/2025/02/12/gensight-biologics-annonce-les-resultats-defficacite-et-de-securite-a-cinq-ans-de-la-therapie-genique-lumevoq-a-lissue-de-letude-reflect/ 2026-09-24T04:05:47+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/REFLECT-Year-5-FIGURE-CURVES.png https://www.gensight-biologics.com/wp-content/uploads/2025/02/REFLECT-Year-5-FIGURE-CURVES-500x375.png https://www.gensight-biologics.com/wp-content/uploads/2025/02/REFLECT-Year-5-GRAPH-TABLE-fr-500x58.png https://www.gensight-biologics.com/fr/2025/01/23/gensight-biologics-publie-sa-situation-nette-de-tresorerie-a-la-fin-de-lannee-2024-et-fait-le-point-sur-ses-activites/ 2026-09-24T04:05:47+00:00 https://www.gensight-biologics.com/fr/2024/12/24/gensight-biologics-annonce-un-financement-dun-montant-denviron-15-million-deuros-aupres-dinvestisseurs-existants-2/ 2026-09-24T04:05:48+00:00 https://www.gensight-biologics.com/fr/2025/01/15/gensight-biologics-annonce-la-publication-des-resultats-cliniques-a-cinq-ans-pour-les-patients-traites-unilateralement-avec-la-therapie-genique-lumevoq/ 2026-09-24T04:05:48+00:00 https://www.gensight-biologics.com/fr/2024/12/18/gensight-biologics-fait-un-point-sur-les-discussions-reglementaires-et-sa-situation-financiere/ 2026-09-24T04:05:48+00:00 https://www.gensight-biologics.com/fr/2024/10/28/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl/ 2026-09-24T04:05:49+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Meta-Analyses-Figure-1-FR-website.jpg https://www.gensight-biologics.com/wp-content/uploads/2024/10/Meta-Analyses-Figure-1-FR-website-500x375.jpg https://www.gensight-biologics.com/fr/2024/11/13/gensight-biologics-annonce-la-soumission-du-dossier-lumevoq-a-lansm-pour-preparer-la-reprise-du-programme-dacces-compassionnel-en-france/ 2026-09-24T04:05:49+00:00 https://www.gensight-biologics.com/fr/2024/11/01/pricing-offering/ 2026-09-24T04:05:49+00:00 https://www.gensight-biologics.com/fr/2024/10/17/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-de-laao/ 2026-09-24T04:05:50+00:00 https://www.gensight-biologics.com/fr/2024/10/24/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2024-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:05:50+00:00 https://www.gensight-biologics.com/fr/2024/09/23/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2023-et-un-point-sur-ses-activites/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/07/23/gensight-biologics-publie-sa-position-de-tresorerie-au-30-juin-2024-et-fait-le-point-sur-ses-activites/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/05/07/gensight-biologics-annonce-le-succes-dune-offre-dun-montant-de-plus-de-92-millions-deuros/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/05/07/gensight-biologics-annonce-la-mise-a-disposition-dun-prospectus-a-loccasion-de-ladmission-dactions-nouvelles-sur-euronext-paris-2/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/06/04/gensight-biologics-invite-a-presenter-aux-prochaines-conferences-medicales-et-reunions-scientifiques/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/05/30/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/06/03/gensight-biologics-nomme-william-monteith-a-son-conseil-dadministration/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/06/20/12267/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/07/11/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2024/05/07/assemblee-generale-mixte-du-29-mai-2024/ 2026-09-24T04:05:51+00:00 https://www.gensight-biologics.com/fr/2023/11/21/gensight-biologics-annonce-le-succes-dune-offre-dun-montant-denviron-47-millions-deuros/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2023/11/22/gensight-biologics-annonce-la-mise-a-disposition-dun-prospectus-a-loccasion-de-ladmission-dactions-nouvelles-sur-euronext-paris/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2023/12/22/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2023/12/27/gensight-biologics-fait-un-point-sur-sa-situation-operationnelle-et-financiere/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/01/16/laurence-rodriguez-nommee-directrice-generale-de-gensight-biologics-en-decembre-2023-rejoint-le-conseil-dadministration-de-la-societe/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/01/25/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-decembre-2023-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/02/08/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Table-CP.png https://www.gensight-biologics.com/wp-content/uploads/2024/02/Table-CP-500x239.png https://www.gensight-biologics.com/fr/2024/03/04/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/03/06/gensight-biologics-annonce-de-nouvelles-donnees-de-vraie-vie-issues-des-programmes-dacces-precoce-de-la-therapie-geniques-lumevoq-au-congres-de-nanos-2024/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/BCVA-Early-Access-CP-2024.png https://www.gensight-biologics.com/wp-content/uploads/2024/03/BCVA-Early-Access-CP-2024-500x487.png https://www.gensight-biologics.com/fr/2024/03/12/nanos-2024-gensight-biologics-annonce-les-premiers-resultats-issus-de-nouvelles-meta-analyses-sur-lamelioration-de-la-vision-obtenue-avec-la-therapie-genique-lumevoq/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Figure-1-ENG-for-website.png https://www.gensight-biologics.com/wp-content/uploads/2024/03/Figure-1-ENG-for-website-500x203.png https://www.gensight-biologics.com/fr/2024/03/20/gensight-biologics-confirme-lefficacite-et-la-securite-durables-des-injections-bilaterales-de-lumevoq-quatre-ans-apres-une-administration-unique/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graphique-1-BCVA-au-fils-du-temps.jpg https://www.gensight-biologics.com/wp-content/uploads/2024/03/Graphique-1-BCVA-au-fils-du-temps-470x500.jpg https://www.gensight-biologics.com/wp-content/uploads/2024/03/Tableau-1-BCVA-par-rapport-au-nadir-500x340.jpg https://www.gensight-biologics.com/fr/2024/03/22/gensight-biologics-publie-ses-resultats-financiers-consolides-pour-lexercice-2023/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/04/04/gensight-biologics-annonce-son-calendrier-financier-pour-2024/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/04/04/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2024-et-fait-le-point-sur-ses-activites/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2024/04/17/11811/ 2026-09-24T04:05:52+00:00 https://www.gensight-biologics.com/fr/2023/03/24/gensight-biologics-publie-ses-resultats-financiers-consolides-pour-lexercice-2022/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/04/04/gensight-biologics-tiendra-un-webcast-le-5-avril-2023-pour-faire-le-point-sur-la-production-de-lumevoq-suite-aux-resultats-des-investigations/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/04/20/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/04/21/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2023-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/07/20/gensight-biologics-fait-un-point-sur-sa-situation-financiere-et-operationnelle/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/05/10/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2022-et-reprogramme-son-assemblee-generale-annuelle-le-21-juin-2023/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/09/15/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2023/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/05/31/assemblee-generale-mixte-du-21-juin-2023/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/08/03/gensight-biologics-obtient-un-financement-de-10-millions-deuros-de-sofinnova-partners-invus-et-upmc-enterprises/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/09/18/gensight-biologics-annonce-avoir-produit-un-lot-gmp-de-lumevoq-avec-succes/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/09/27/gensight-biologics-fait-un-point-sur-lavis-scientifique-de-lagence-europeenne-des-medicaments-pour-lumevoq/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/10/26/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2023-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/11/13/gensight-biologics-annonce-les-resultats-preliminaires-dun-2nd-lot-gmp-de-lumevoq-produit-avec-succes/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/11/15/gensight-biologics-confirme-le-succes-du-2nd-lot-gmp-de-lumevoq-et-leligibilite-a-tirer-la-2eme-tranche-de-4-millions-deuros-du-financement-relais/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/11/20/gensight-biologics-annonce-le-lancement-dune-offre-pour-un-montant-indicatif-de-5-millions-deuros-avec-engagements-de-souscription-dactionnaires-nouveaux-et-existants-pour-un-montant-total-de-4/ 2026-09-24T04:05:53+00:00 https://www.gensight-biologics.com/fr/2023/03/09/gensight-biologics-annonce-la-publication-des-donnees-de-securite-de-lumevoq-sur-une-periode-de-5-ans-dans-le-celebre-journal-a-comite-de-lecture-american-journal-of-ophthalmology/ 2026-09-24T04:05:54+00:00 https://www.gensight-biologics.com/fr/2023/03/10/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-medicales-2/ 2026-09-24T04:05:54+00:00 https://www.gensight-biologics.com/fr/2023/03/13/gensight-biologics-confirme-le-maintien-de-lefficacite-et-de-la-tolerance-dune-injection-bilaterale-de-lumevoq-apres-3-ans-dans-lessai-de-phase-iii-reflect/ 2026-09-24T04:05:54+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-1-3.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/Graph-1-500x364.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/EN-tab-2-500x176.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/TAB-1-EN-500x274.jpg https://www.gensight-biologics.com/fr/2023/03/15/gensight-biologics-annonce-la-presentation-des-donnees-defficacite-et-de-tolerance-de-lumevoq-issues-des-programmes-dacces-precoce-pour-les-patients-atteints-de-nohl-nd4-au-congres-2023-du-n/ 2026-09-24T04:05:54+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/Graph-466x500.jpg https://www.gensight-biologics.com/fr/2023/02/28/journee-des-maladies-rares-2023-gensight-biologics-sensibilise-a-la-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:06:58+00:00 https://www.gensight-biologics.com/fr/2023/02/28/gensight-biologics-annonce-son-calendrier-financier-pour-2023/ 2026-09-24T04:06:58+00:00 https://www.gensight-biologics.com/fr/2023/03/07/gensight-biologics-fait-le-point-sur-le-calendrier-de-production-et-de-commercialisation-de-lumevoq/ 2026-09-24T04:06:58+00:00 https://www.gensight-biologics.com/fr/2023/02/06/gensight-biologics-annonce-le-tirage-de-la-premiere-tranche-de-8-millions-deuros-dans-le-cadre-de-son-contrat-de-credit-avec-la-banque-europeenne-dinvestissement/ 2026-09-24T04:06:59+00:00 https://www.gensight-biologics.com/fr/2023/02/13/gensight-biologics-annonce-les-donnees-de-securite-et-des-signaux-defficacite-a-1-an-de-letude-de-phase-i-ii-pioneer-avec-gs030-son-candidat-traitement-optogenetique-de-la-retinopathie-pigmentair/ 2026-09-24T04:06:59+00:00 https://www.gensight-biologics.com/fr/2022/12/23/gensight-biologics-obtient-12-millions-deuros-de-financement-par-une-emission-obligataire-convertible-avec-prime-souscrite-par-un-investisseur-institutionnel-et-fait-le-point-sur-ses-activites/ 2026-09-24T04:07:00+00:00 https://www.gensight-biologics.com/fr/2023/01/04/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs/ 2026-09-24T04:07:00+00:00 https://www.gensight-biologics.com/fr/2023/01/26/10104/ 2026-09-24T04:07:00+00:00 https://www.gensight-biologics.com/fr/2022/11/17/gensight-biologics-annonce-la-publication-des-resultats-de-letude-clinique-pivot-reflect-de-lumevoq-dans-des-revues-scientifiques-a-comite-de-lecture/ 2026-09-24T04:07:01+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Figure-1-REFLECT-TITRE.jpg https://www.gensight-biologics.com/fr/2022/12/15/gensight-biologics-annonce-la-publication-dans-la-revue-scientifique-a-comite-de-lecture-ophthalmology-and-therapy-de-la-comparaison-indirecte-entre-lumevoq%ef%83%92-et-lhistoire-naturelle-chez-les/ 2026-09-24T04:07:01+00:00 https://www.gensight-biologics.com/fr/2022/09/29/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-medicales/ 2026-09-24T04:07:02+00:00 https://www.gensight-biologics.com/fr/2022/10/28/gensight-biologics-publie-sa-situation-nette-de-tresorerie-et-son-chiffre-daffaires-au-30-septembre-2022/ 2026-09-24T04:07:02+00:00 https://www.gensight-biologics.com/fr/2022/11/04/gensight-biologics-obtient-un-credit-dun-montant-de-35-millions-deuros-de-la-banque-europeenne-dinvestissement-pour-accompagner-la-mise-sur-le-marche-de-lumevoq-en-europe/ 2026-09-24T04:07:02+00:00 https://www.gensight-biologics.com/fr/2022/09/19/gensight-biologics-annonce-le-succes-de-la-production-du-lot-pilote-de-lumevoq-validant-les-actions-correctives-mises-en-oeuvre/ 2026-09-24T04:07:03+00:00 https://www.gensight-biologics.com/fr/2022/09/20/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-industrie-et-investisseurs/ 2026-09-24T04:07:03+00:00 https://www.gensight-biologics.com/fr/2022/09/12/gensight-biologics-renforce-son-equipe-de-direction-pour-soutenir-le-lancement-de-lumevoq-en-europe/ 2026-09-24T04:07:04+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Philippe-Motte-e1662963007510.png https://www.gensight-biologics.com/fr/2022/07/28/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2022/ 2026-09-24T04:07:04+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/resultats-intermediaires.jpg https://www.gensight-biologics.com/fr/2022/07/20/gensight-biologics-publie-des-donnees-montrant-une-efficacite-et-une-securite-durables-5-ans-apres-un-traitement-unique-avec-lumevoq/ 2026-09-24T04:07:05+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-def.jpg https://www.gensight-biologics.com/fr/2022/06/16/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022/ 2026-09-24T04:07:05+00:00 https://www.gensight-biologics.com/fr/2022/05/19/gensight-biologics-annonce-la-publication-dans-le-journal-of-neuro-ophthalmology-dune-etude-de-limpact-de-la-nohl-sur-la-vie-des-patients-et-de-leurs-proches/ 2026-09-24T04:07:05+00:00 https://www.gensight-biologics.com/fr/2022/05/04/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee/ 2026-09-24T04:07:06+00:00 https://www.gensight-biologics.com/fr/2022/04/29/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021/ 2026-09-24T04:07:06+00:00 https://www.gensight-biologics.com/fr/2022/04/21/gensight-biologics-publie-sa-situation-nette-de-tresorerie-et-son-chiffre-daffaires-au-31-mars-2022/ 2026-09-24T04:07:07+00:00 https://www.gensight-biologics.com/fr/2022/04/14/gensight-biologics-obtient-une-prolongation-de-six-mois-de-lexamen-reglementaire-europeen-de-lumevoq/ 2026-09-24T04:07:07+00:00 https://www.gensight-biologics.com/fr/2022/04/08/gensight-biologics-publie-ses-resultats-financiers-consolides-2021/ 2026-09-24T04:07:07+00:00 https://www.gensight-biologics.com/fr/2022/04/07/gensight-biologics-fait-le-point-sur-le-calendrier-de-production-de-lumevoq/ 2026-09-24T04:07:08+00:00 https://www.gensight-biologics.com/fr/2022/03/11/gensight-biologics-annonce-son-calendrier-financier-pour-2022/ 2026-09-24T04:07:08+00:00 https://www.gensight-biologics.com/fr/2022/02/14/gensight-biologics-biologics-presentera-les-resultats-de-letude-de-phase-iii-reflect-de-lumevoq-au-congres-2022-du-nanos/ 2026-09-24T04:07:08+00:00 https://www.gensight-biologics.com/fr/2022/02/01/gensight-biologics-nomme-sissel-rodahl-comme-vice-president-senior-des-operations-commerciales-pour-diriger-le-lancement-de-lumevoq-en-europe/ 2026-09-24T04:07:09+00:00 https://www.gensight-biologics.com/fr/2022/01/24/gensight-biologics-annonce-le-maintien-de-lamelioration-cliniquement-significative-de-la-vision-4-ans-apres-une-seule-injection-de-la-therapie-genique-lumevoq/ 2026-09-24T04:07:09+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/LOESS-curves-RESTORE-Year-4.jpg https://www.gensight-biologics.com/fr/2022/01/18/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-decembre-2021-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:07:10+00:00 https://www.gensight-biologics.com/fr/2021/12/14/gensight-biologics-confirme-le-maintien-de-lefficacite-et-de-la-tolerance-dune-injection-bilaterale-de-lumevoq-apres-2-ans-dans-lessai-de-phase-iii-reflect/ 2026-09-24T04:07:10+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/REFLECT-Year-2-BCVA-from-baseline.png https://www.gensight-biologics.com/wp-content/uploads/2021/12/REFLECT-Year-2-BCVA-from-baseline-500x331.png https://www.gensight-biologics.com/fr/2021/12/01/gensight-biologics-annonce-la-publication-dune-etude-rapportant-la-presence-de-vecteur-adn-de-lumevoq-dans-les-yeux-controlateraux-apres-injection-unilaterale-chez-des-primates-non-huma/ 2026-09-24T04:07:10+00:00 https://www.gensight-biologics.com/fr/2021/11/30/gensight-biologics-tiendra-un-webcast-avec-un-leader-dopinion-sur-les-resultats-des-patients-traites-bilateralement-avec-lumevoq-en-usage-compassionnel-aux-etats-unis-2/ 2026-09-24T04:07:11+00:00 https://www.gensight-biologics.com/fr/2021/11/23/gensight-biologics-invite-julien-secheyron-patient-n15-de-la-1ere-etude-clinique-de-lumevoq-a-venir-presenter-son-livre-vous-ne-verrez-plus/ 2026-09-24T04:07:11+00:00 https://www.gensight-biologics.com/fr/2021/11/22/gensight-biologics-tiendra-un-webcast-avec-un-leader-dopinion-sur-les-resultats-des-patients-traites-bilateralement-avec-lumevoq-en-usage-compassionnel-aux-etats-unis/ 2026-09-24T04:07:11+00:00 https://www.gensight-biologics.com/fr/2021/11/15/article-fr/ 2026-09-24T04:07:12+00:00 https://www.gensight-biologics.com/fr/2021/11/17/gensight-biologics-rapporte-un-second-cas-de-recuperation-visuelle-chez-une-patiente-traitee-avec-la-therapie-optogenetique-gs030/ 2026-09-24T04:07:12+00:00 https://www.gensight-biologics.com/fr/2021/11/15/gensight-biologics-annonce-la-prolongation-par-lema-de-la-periode-de-clock-stop-a-120-jours-du-dossier-reglementaire-de-lumevoq-la-procedure-dexamen-reprendra-desormai/ 2026-09-24T04:07:13+00:00 https://www.gensight-biologics.com/fr/2021/11/12/gensight-biologics-presentera-de-nouveaux-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-au-congres-2021-de-lamerican-academy-of-ophthalmology/ 2026-09-24T04:07:13+00:00 https://www.gensight-biologics.com/fr/2021/11/10/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2021-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:07:13+00:00 https://www.gensight-biologics.com/fr/2021/11/04/gensight-biologics-annonce-loctroi-par-la-fda-de-la-designation-fast-track-pour-gs030-comme-traitement-optogenetique-de-la-retinopathie-pigmentaire-2/ 2026-09-24T04:07:14+00:00 https://www.gensight-biologics.com/fr/2021/10/12/gensight-biologics-annonce-loctroi-par-la-fda-de-la-designation-fast-track-pour-gs030-comme-traitement-optogenetique-de-la-retinopathie-pigmentaire/ 2026-09-24T04:07:14+00:00 https://www.gensight-biologics.com/fr/2021/10/06/gensight-biologics-annonce-la-publication-dune-revue-des-essais-de-therapie-genique-pour-la-nohl-dans-international-ophthalmology-clinics/ 2026-09-24T04:07:14+00:00 https://www.gensight-biologics.com/fr/2021/10/04/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-aux-congres-2021-de-lasrs-et-de-lesgct-ainsi-qua-plusieurs-conf/ 2026-09-24T04:07:15+00:00 https://www.gensight-biologics.com/fr/2021/09/15/gensight-biologics-annonce-les-conclusions-positives-du-data-safety-monitoring-board-dsmb-de-letude-clinique-de-phase-i-ii-pioneer-de-gs030-comme-traitement-optogenetique-de-la-retinopathie/ 2026-09-24T04:07:15+00:00 https://www.gensight-biologics.com/fr/2021/09/09/gensight-biologics-annonce-la-publication-dune-analyse-des-parametres-visuels-chez-les-sujets-atteints-de-nd4-nohl-avant-traitement-avec-lumevoq-dans-les-etudes-de-phase-iii/ 2026-09-24T04:07:16+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/R-R-BSL.png https://www.gensight-biologics.com/wp-content/uploads/2021/09/R-R-BSL.png https://www.gensight-biologics.com/fr/2021/09/06/la-mhra-accorde-le-statut-de-promising-innovative-medicine-au-royaume-uni-a-la-therapie-genique-lumevoq-de-gensight-biologics/ 2026-09-24T04:07:16+00:00 https://www.gensight-biologics.com/fr/2021/09/01/les-resultats-cliniques-des-therapies-geniques-lumevoq-et-gs030-de-gensight-biologics-seront-presentes-au-congres-2021-de-lisgedr-ainsi-qua-plusieurs-conferences-investisseurs/ 2026-09-24T04:07:16+00:00 https://www.gensight-biologics.com/fr/2021/08/31/gensight-biologics-annonce-la-publication-des-donnees-de-letude-restore-demontrant-lefficacite-prolongee-de-lumevoq-3-ans-apres-injection-unilaterale/ 2026-09-24T04:07:17+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-restore-3y-FU-PR-31AUG2021.png https://www.gensight-biologics.com/wp-content/uploads/2021/08/Graph-restore-3y-FU-PR-31AUG2021.png https://www.gensight-biologics.com/fr/2021/07/29/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2021-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:07:17+00:00 https://www.gensight-biologics.com/fr/2021/07/05/gensight-biologics-tiendra-des-webcasts-avec-des-leaders-dopinion-sur-les-resultats-de-letude-clinique-de-phase-iii-reflect-de-lumevoq/ 2026-09-24T04:07:18+00:00 https://www.gensight-biologics.com/fr/2021/07/05/gensight-biologics-annonce-loctroi-dune-autorisation-temporaire-dutilisation-de-cohorte-atuc-pour-lumevoq-en-france/ 2026-09-24T04:07:18+00:00 https://www.gensight-biologics.com/fr/2021/06/30/gensight-biologics-annonce-les-resultats-de-letude-clinique-de-phase-iii-reflect-confirmant-lefficacite-de-lumevoq-et-demontrant-une-meilleure-efficacite-du-traitement-bilater/ 2026-09-24T04:07:19+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-1.jpg https://www.gensight-biologics.com/wp-content/uploads/2021/06/Graph-1.jpg https://www.gensight-biologics.com/wp-content/uploads/2021/06/Graph-2.jpg https://www.gensight-biologics.com/fr/2021/06/10/gensight-biologics-nomme-marion-ghibaudo-comme-directeur-technique-pour-diriger-lingenierie-du-dispositif-de-stimulation-visuelle-de-gs030/ 2026-09-24T04:07:19+00:00 https://www.gensight-biologics.com/fr/2021/06/01/gensight-biologics-annonce-la-publication-dans-frontiers-in-neurology-de-la-comparaison-indirecte-montrant-leffet-du-traitement-par-lumevoq-compare-a-lhistoire-naturelle/ 2026-09-24T04:07:19+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-graph-Ind-Comp-LHOn-May-2021.png https://www.gensight-biologics.com/wp-content/uploads/2021/05/Image-graph-Ind-Comp-LHOn-May-2021.png https://www.gensight-biologics.com/fr/2021/05/31/gensight-biologics-tiendra-un-webinaire-avec-des-leaders-dopinion-sur-la-publication-dans-nature-medicine-dun-cas-de-recuperation-visuelle-apres-traitement-optogenetique-par-gs030/ 2026-09-24T04:07:20+00:00 https://www.gensight-biologics.com/fr/2021/05/25/gensight-biologics-annonce-la-publication-dans-nature-medicine-dun-cas-de-recuperation-visuelle-apres-traitement-optogenetique-par-gs030/ 2026-09-24T04:07:20+00:00 https://www.gensight-biologics.com/fr/2021/04/08/assemblee-generale-mixte-du-29-avril-2021/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/fr/2021/04/08/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/fr/2021/04/20/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2021-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/fr/2021/05/19/gensight-biologics-nomme-ses-directeurs-des-operations-en-france-en-allemagne-et-au-royaume-uni-pour-preparer-le-lancement-commercial-de-lumevoq/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/fr/2021/05/03/gensight-biologics-annonce-la-publication-des-resultats-de-letude-dhistoire-naturelle-de-la-nohl-reality-dans-la-revue-eye/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-graph-Reality-Paper.png https://www.gensight-biologics.com/wp-content/uploads/2021/05/Image-graph-Reality-Paper.png https://www.gensight-biologics.com/fr/2021/05/14/gensight-biologics-fait-le-point-sur-ses-operations-en-2021-dans-le-contexte-covid-19/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/fr/2021/05/17/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration/ 2026-09-24T04:07:21+00:00 https://www.gensight-biologics.com/fr/2021/03/10/gensight-biologics-publie-ses-resultats-financiers-2020-et-fait-un-point-sur-les-principaux-enjeux-2021/ 2026-09-24T04:07:22+00:00 https://www.gensight-biologics.com/fr/2021/03/25/gensight-biologics-lance-une-offre-reservee-dun-montant-denviron-25-millions-deuros-par-construction-acceleree-dun-livre-dordres/ 2026-09-24T04:07:22+00:00 https://www.gensight-biologics.com/fr/2021/03/26/gensight-biologics-leve-avec-succes-30-millions-deuros-dans-un-placement-prive-sursouscrit-aupres-dinvestisseurs-institutionnels-europeens-et-americains/ 2026-09-24T04:07:22+00:00 https://www.gensight-biologics.com/fr/2021/01/19/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-decembre-2020-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:35+00:00 https://www.gensight-biologics.com/fr/2021/02/04/gensight-biologics-annonce-la-publication-dans-communications-biology-de-la-preuve-de-concept-pour-gs030-drug-product-chez-le-singe/ 2026-09-24T04:08:35+00:00 https://www.gensight-biologics.com/fr/2021/02/15/gensight-biologics-annonce-la-publication-des-resultats-de-lessai-clinique-de-phase-i-iia-reveal-de-lumevoq-dans-la-revue-biodrugs/ 2026-09-24T04:08:35+00:00 https://www.gensight-biologics.com/fr/2021/01/13/gensight-biologics-annonce-la-publication-dans-la-revue-ophthalmology-des-resultats-de-lessai-pivot-de-phase-iii-rescue-avec-lumevoq/ 2026-09-24T04:08:36+00:00 https://www.gensight-biologics.com/fr/2021/01/18/gensight-biologics-annonce-son-calendrier-financier-pour-2021/ 2026-09-24T04:08:36+00:00 https://www.gensight-biologics.com/fr/2020/12/10/gensight-biologics-annonce-la-conversion-partielle-des-obligations-convertibles-et-lexercice-de-lintegralite-des-bons-de-souscription-dactions-par-kreos-capital/ 2026-09-24T04:08:36+00:00 https://www.gensight-biologics.com/fr/2020/12/10/gensight-biologics-annonce-la-publication-dans-science-translational-medicine-des-resultats-de-lessai-pivot-de-phase-iii-reverse-et-dune-etude-sur-des-primates-avec-lumevoq/ 2026-09-24T04:08:37+00:00 https://www.gensight-biologics.com/fr/2020/11/03/gensight-biologics-annonce-la-validation-de-la-demande-dautorisation-de-mise-sur-le-marche-amm-de-lumevoq-par-lagence-europeenne-des-medicaments/ 2026-09-24T04:08:37+00:00 https://www.gensight-biologics.com/fr/2020/10/22/gensight-biologics-leve-avec-succes-25-millions-deuros-dans-un-placement-prive-sursouscrit-aupres-dinvestisseurs-institutionnels-europeens-et-americains/ 2026-09-24T04:08:37+00:00 https://www.gensight-biologics.com/fr/2020/10/15/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2020-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:38+00:00 https://www.gensight-biologics.com/fr/2020/10/21/gensight-biologics-lance-une-augmentation-de-capital-dun-montant-denviron-25-millions-deuros-par-construction-acceleree-dun-livre-dordres-2/ 2026-09-24T04:08:38+00:00 https://www.gensight-biologics.com/fr/2020/09/28/gensight-biologics-annonce-la-publication-dune-meta-analyse-confirmant-que-la-recuperation-spontanee-dans-la-nohl-est-rare-dans-le-journal-of-neuro-ophthalmology/ 2026-09-24T04:08:39+00:00 https://www.gensight-biologics.com/fr/2020/10/14/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration/ 2026-09-24T04:08:39+00:00 https://www.gensight-biologics.com/fr/2020/09/21/gensight-biologics-publie-une-nouvelle-analyse-mettant-en-evidence-une-difference-statistiquement-et-cliniquement-significative-entre-les-resultats-visuels-des-patients-traites-par-lumevoq-et-l/ 2026-09-24T04:08:39+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/image-graph.png https://www.gensight-biologics.com/wp-content/uploads/2020/09/image-graph.png https://www.gensight-biologics.com/fr/2020/09/15/gensight-biologics-soumet-une-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq-sa-therapie-genique-pour-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber-n/ 2026-09-24T04:08:40+00:00 https://www.gensight-biologics.com/fr/2020/08/04/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital/ 2026-09-24T04:08:40+00:00 https://www.gensight-biologics.com/fr/2020/07/30/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2020-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:41+00:00 https://www.gensight-biologics.com/fr/2020/07/21/gensight-biologics-publie-les-resultats-complets-de-letude-dhistoire-naturelle-reality-confirmant-labsence-de-recuperation-fonctionnelle-spontanee-des-patients-atteints-de-n/ 2026-09-24T04:08:41+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph_Reality-full.png https://www.gensight-biologics.com/fr/2020/07/15/bilan-semestriel-du-contrat-de-liquidite-contracte-avec-oddo-bhf/ 2026-09-24T04:08:41+00:00 https://www.gensight-biologics.com/fr/2020/07/09/gensight-biologics-obtient-un-pret-non-dilutif-de-7-millions-deuros-et-renegocie-lemprunt-obligataire-avec-kreos-capital-portant-lhorizon-de-financement-a-mi-2021/ 2026-09-24T04:08:42+00:00 https://www.gensight-biologics.com/fr/2020/07/06/gensight-biologics-confirme-lefficacite-et-la-securite-de-lumevoq-chez-des-patients-atteints-de-nohl-trois-ans-apres-le-traitement/ 2026-09-24T04:08:42+00:00 https://www.gensight-biologics.com/fr/2020/07/02/gensight-biologics-tiendra-une-conference-telephonique-sur-lumevoq-avec-des-leaders-dopinion-le-9-juillet-2020/ 2026-09-24T04:08:42+00:00 https://www.gensight-biologics.com/fr/2020/04/22/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos/ 2026-09-24T04:08:43+00:00 https://www.gensight-biologics.com/fr/2020/04/21/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2020-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:43+00:00 https://www.gensight-biologics.com/fr/2020/04/15/gensight-biologics-confirme-son-intention-de-soumettre-le-dossier-de-lumevoq-en-europe-en-septembre-2020-a-lissue-de-la-reunion-de-pre-soumission-avec-lema/ 2026-09-24T04:08:44+00:00 https://www.gensight-biologics.com/fr/2020/04/14/gensight-biologics-annonce-les-conclusions-positives-du-data-safety-monitoring-board-dsmb-de-letude-de-phase-i-ii-pioneer-de-gs030-combinant-therapie-genique-et-optogenetique-dans-le-traite/ 2026-09-24T04:08:44+00:00 https://www.gensight-biologics.com/fr/2020/04/08/assemblee-generale-mixte-du-29-avril-2020-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee/ 2026-09-24T04:08:44+00:00 https://www.gensight-biologics.com/fr/2020/04/08/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2019/ 2026-09-24T04:08:45+00:00 https://www.gensight-biologics.com/fr/2020/04/06/gensight-biologics-fait-le-point-sur-ses-activites-dans-le-contexte-covid-19/ 2026-09-24T04:08:45+00:00 https://www.gensight-biologics.com/fr/2020/03/12/gensight-biologics-publie-ses-resultats-financiers-2019-et-fait-un-point-sur-les-principaux-enjeux-2020/ 2026-09-24T04:08:45+00:00 https://www.gensight-biologics.com/fr/2020/03/03/gensight-biologics-annonce-la-presentation-de-la-recuperation-visuelle-bilaterale-observee-dans-les-etudes-de-phase-iii-avec-gs010-lumevoq-au-46eme-congres-annuel-du-nanos/ 2026-09-24T04:08:46+00:00 https://www.gensight-biologics.com/fr/2020/01/21/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-decembre-2019-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:46+00:00 https://www.gensight-biologics.com/fr/2020/01/20/gensight-biologics-annonce-son-calendrier-financier-pour-2020/ 2026-09-24T04:08:47+00:00 https://www.gensight-biologics.com/fr/2019/12/20/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2018/ 2026-09-24T04:08:47+00:00 https://www.gensight-biologics.com/fr/2019/12/20/gensight-biologics-obtient-15-millions-deuros-de-financement-par-une-emission-obligataire-souscrite-par-kreos-capital-et-une-augmentation-de-capital-reservee-a-sofinnova-et-3sbio/ 2026-09-24T04:08:47+00:00 https://www.gensight-biologics.com/fr/2019/12/11/gensight-biologics-annonce-les-premiers-resultats-de-letude-reality-et-met-en-evidence-les-benefices-de-lumevoq-gs010-par-rapport-a-lhistoire-naturelle-de-la-nohl/ 2026-09-24T04:08:48+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Reality_image-1.png https://www.gensight-biologics.com/fr/2019/10/09/gensight-biologics-met-en-evidence-le-passage-de-ladn-du-gs010-dans-loeil-controlateral-chez-des-primates-ayant-recu-une-injection-unilaterale-de-la-therapie-genique-gs010/ 2026-09-24T04:08:50+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-grapgh-NHP.png https://www.gensight-biologics.com/wp-content/uploads/2019/10/Image-grapgh-NHP.png https://www.gensight-biologics.com/fr/2019/10/22/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2019-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:50+00:00 https://www.gensight-biologics.com/fr/2019/12/09/lhopital-des-quinze-vingts-et-gensight-biologics-annoncent-une-1ere-autorisation-temporaire-dutilisation-atu-de-lumevoq-gs010-en-france/ 2026-09-24T04:08:50+00:00 https://www.gensight-biologics.com/fr/2019/10/08/gensight-biologics-presentera-de-nouveaux-resultats-de-gs010-au-congres-annuel-2019-de-lamerican-academy-of-ophthalmology/ 2026-09-24T04:08:51+00:00 https://www.gensight-biologics.com/fr/2019/10/08/gensight-biologics-nomme-magali-taiel-au-poste-de-directeur-medical/ 2026-09-24T04:08:51+00:00 https://www.gensight-biologics.com/fr/2019/10/01/gensight-biologics-integre-lindice-enternext-pea-pme-150-deuronext/ 2026-09-24T04:08:51+00:00 https://www.gensight-biologics.com/fr/2019/09/23/gensight-biologics-annonce-une-efficacite-et-une-securite-prolongees-de-gs010-a-96-semaines-dans-son-etude-clinique-de-phase-iii-rescue-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-lebe/ 2026-09-24T04:08:52+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Time-course_ENG.png https://www.gensight-biologics.com/wp-content/uploads/2019/09/Time-course_ENG.png https://www.gensight-biologics.com/wp-content/uploads/2019/09/Time-course-2_ENG.png https://www.gensight-biologics.com/fr/2019/07/24/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2019-et-fait-un-point-sur-ses-activites/ 2026-09-24T04:08:52+00:00 https://www.gensight-biologics.com/fr/2019/07/11/gensight-biologics-annonce-la-fin-du-recrutement-de-son-etude-de-phase-iii-reflect-avec-gs010-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber-en-avance-par-rapport-aux-objectifs/ 2026-09-24T04:08:53+00:00 https://www.gensight-biologics.com/fr/2019/06/18/gensight-biologics-annonce-la-presentation-des-resultats-de-letude-clinique-de-phase-iii-reverse-avec-gs010-au-congres-2019-de-leunos/ 2026-09-24T04:08:53+00:00 https://www.gensight-biologics.com/fr/2019/06/19/gensight-biologics-renforce-son-conseil-dadministration-avec-les-nominations-de-maritza-mcintyre-et-sofinnova-partners/ 2026-09-24T04:08:53+00:00 https://www.gensight-biologics.com/fr/2019/05/23/gensight-biologics-tiendra-une-presentation-investisseurs-a-new-york-le-23-mai-2019/ 2026-09-24T04:08:54+00:00 https://www.gensight-biologics.com/fr/2019/05/29/des-leaders-dopinion-concluent-que-lamelioration-bilaterale-durable-observee-dans-letude-clinique-de-phase-iii-reverse-de-gensight-biologics-represente-un-benefice-therapeut/ 2026-09-24T04:08:54+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/image-1.png https://www.gensight-biologics.com/wp-content/uploads/2019/05/image-1.png https://www.gensight-biologics.com/wp-content/uploads/2019/05/image-2.png https://www.gensight-biologics.com/fr/2019/05/07/gensight-biologics-annonce-les-conclusions-positives-du-data-safety-monitoring-board-dsmb-et-la-poursuite-de-letude-clinique-de-phase-i-ii-pioneer-de-gs030-combinant-therapie-genique-et-opt/ 2026-09-24T04:08:55+00:00 https://www.gensight-biologics.com/fr/2019/05/15/gensight-biologics-annonce-les-resultats-positifs-a-96-semaines-de-letude-clinique-de-phase-iii-reverse-avec-gs010-dans-la-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:08:55+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/image-VA-FR.png https://www.gensight-biologics.com/wp-content/uploads/2019/05/image-VA-FR.png https://www.gensight-biologics.com/wp-content/uploads/2019/05/image-CS-FR.png https://www.gensight-biologics.com/fr/2019/05/21/assemblee-generale-mixte-du-11-juin-2019/ 2026-09-24T04:08:55+00:00 https://www.gensight-biologics.com/fr/2019/05/06/gensight-biologics-annonce-la-presentation-des-resultats-a-72-semaines-de-letude-de-phase-iii-reverse-avec-gs010-au-congres-2019-de-lamerican-academy-of-neurology-aan/ 2026-09-24T04:09:39+00:00 https://www.gensight-biologics.com/fr/2019/04/25/gensight-biologics-annonce-la-presentation-des-resultats-a-72-semaines-des-etudes-cliniques-de-phase-iii-reverse-rescue-avec-gs010-au-congres-2019-de-larvo/ 2026-09-24T04:09:40+00:00 https://www.gensight-biologics.com/fr/2019/04/29/gensight-biologics-met-a-disposition-son-rapport-financier-annuel-2018/ 2026-09-24T04:09:40+00:00 https://www.gensight-biologics.com/fr/2019/04/17/gensight-biologics-annonce-les-resultats-positifs-de-suivi-a-72-semaines-de-letude-clinique-de-phase-iii-rescue-avec-gs010-dans-la-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:09:41+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/ENG-graph-1.png https://www.gensight-biologics.com/wp-content/uploads/2019/04/ENG-graph-3.png https://www.gensight-biologics.com/fr/2019/04/23/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019/ 2026-09-24T04:09:41+00:00 https://www.gensight-biologics.com/fr/2019/04/24/gensight-biologics-publie-ses-resultats-financiers-2018/ 2026-09-24T04:09:41+00:00 https://www.gensight-biologics.com/fr/2019/02/12/gensight-biologics-annonce-la-publication-de-resultats-de-tolerance-positifs-de-letude-de-phase-i-ii-de-gs010-dans-le-jama-ophthalmology/ 2026-09-24T04:09:42+00:00 https://www.gensight-biologics.com/fr/2019/02/25/gensight-biologics-realise-une-augmentation-de-capital-de-8-me-sans-decote-entierement-souscrite-par-sofinnova/ 2026-09-24T04:09:42+00:00 https://www.gensight-biologics.com/fr/2019/03/15/gensight-biologics-annonce-la-presentation-des-resultats-a-72-semaines-de-letude-clinique-de-phase-iii-reverse-avec-gs010-au-congres-2019-du-nanos/ 2026-09-24T04:09:42+00:00 https://www.gensight-biologics.com/fr/2019/02/04/gensight-biologics-annonce-les-resultats-preliminaires-a-48-semaines-de-letude-clinique-de-phase-iii-rescue-avec-gs010-chez-des-patients-atteints-dune-perte-de-vision-inferieure-a-6/ 2026-09-24T04:09:43+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-1_AV-Rescue.png https://www.gensight-biologics.com/wp-content/uploads/2019/02/Image-1_AV-Rescue.png https://www.gensight-biologics.com/wp-content/uploads/2019/02/Image-2_AV-Rescue-Reverse.png https://www.gensight-biologics.com/fr/2019/02/04/gensight-biologics-met-a-jour-son-calendrier-financier-pour-2019/ 2026-09-24T04:09:43+00:00 https://www.gensight-biologics.com/fr/2018/12/12/gensight-biologics-annonce-des-ameliorations-durables-de-la-qualite-de-vie-a-72-semaines-de-letude-clinique-de-phase-iii-reverse-avec-gs010-dans-le-traitement-de-la-neuropathie-optique-heredi/ 2026-09-24T04:09:44+00:00 https://www.gensight-biologics.com/fr/2019/01/23/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-decembre-2018/ 2026-09-24T04:09:44+00:00 https://www.gensight-biologics.com/fr/2019/01/23/gensight-biologics-annonce-son-calendrier-financier-pour-2019/ 2026-09-24T04:09:44+00:00 https://www.gensight-biologics.com/fr/2018/10/18/gensight-biologics-annonce-des-resultats-positifs-a-72-semaines-de-letude-clinique-de-phase-iii-reverse-avec-gs010-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:09:45+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/72w-PR-FR.jpg https://www.gensight-biologics.com/wp-content/uploads/2018/10/72w-PR-FR.jpg https://www.gensight-biologics.com/fr/2018/10/24/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018/ 2026-09-24T04:09:45+00:00 https://www.gensight-biologics.com/fr/2018/10/26/gensight-biologics-recrute-le-premier-patient-dans-letude-clinique-de-phase-i-ii-pioneer-premiere-chez-lhomme-de-gs030-combinant-therapie-genique-et-optogenetique-dans-le-traitemen/ 2026-09-24T04:09:45+00:00 https://www.gensight-biologics.com/fr/2018/10/09/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs/ 2026-09-24T04:09:46+00:00 https://www.gensight-biologics.com/fr/2018/10/12/gensight-biologics-presentera-des-resultats-de-letude-reverse-de-gs010-au-congres-annuel-2018-de-lamerican-academy-of-ophthalmology/ 2026-09-24T04:09:46+00:00 https://www.gensight-biologics.com/fr/2018/06/20/des-leaders-dopinion-mettent-en-avant-lefficacite-et-les-benefices-patient-de-gs010-lors-de-discussions-autour-de-letude-clinique-de-phase-iii-reverse/ 2026-09-24T04:09:47+00:00 https://www.gensight-biologics.com/fr/2018/07/25/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2018/ 2026-09-24T04:09:47+00:00 https://www.gensight-biologics.com/fr/2018/09/13/gensight-biologics-fait-le-point-sur-les-parcours-clinique-et-reglementaire-de-gs010/ 2026-09-24T04:09:47+00:00 https://www.gensight-biologics.com/fr/2018/04/26/gensight-biologics-presente-des-resultats-de-gs010-et-gs030-au-congres-2018-de-larvo/ 2026-09-24T04:09:48+00:00 https://www.gensight-biologics.com/fr/2018/06/12/gensight-biologics-publie-des-donnees-positives-supplementaires-de-letude-clinique-de-phase-iii-reverse-sur-gs010-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:09:48+00:00 https://www.gensight-biologics.com/fr/2018/04/03/gensight-biologics-annonce-les-resultats-de-lessai-clinique-de-phase-iii-reverse-sur-gs010-chez-des-patients-atteints-de-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:09:49+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/graph_fr.png https://www.gensight-biologics.com/wp-content/uploads/2018/04/graph_fr.png https://www.gensight-biologics.com/fr/2018/02/28/gensight-biologics-publie-ses-resultats-financiers-2017/ 2026-09-24T04:09:49+00:00 https://www.gensight-biologics.com/fr/2018/04/25/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010/ 2026-09-24T04:09:49+00:00 https://www.gensight-biologics.com/fr/2018/01/25/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing/ 2026-09-24T04:09:50+00:00 https://www.gensight-biologics.com/fr/2018/01/25/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite/ 2026-09-24T04:09:50+00:00 https://www.gensight-biologics.com/fr/2018/02/20/gensight-biologics-annonce-la-publication-des-donnees-positives-de-letude-de-phase-i-ii-et-du-suivi-a-long-terme-de-gs010-dans-ophthalmology-la-revue-de-lamerican-academy-of-ophthal/ 2026-09-24T04:09:50+00:00 https://www.gensight-biologics.com/fr/2017/12/05/gensight-biologics-annonce-des-resultats-dacuite-visuelle-et-de-securite-positifs-a-long-terme-avec-gs010-dans-son-etude-de-phase-i-ii-pour-le-traitement-de-la-neuropathie-optique-hereditai/ 2026-09-24T04:09:51+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/gensight-biologics-cp-2.5-years-gs010-ph-i-ii-results-vdef.jpg https://www.gensight-biologics.com/wp-content/uploads/2017/12/gensight-biologics-cp-2.5-years-gs010-ph-i-ii-results-vdef.jpg https://www.gensight-biologics.com/fr/2018/01/10/gensight-biologics-obtient-lautorisation-du-mhra-de-demarrer-letude-clinique-de-phase-i-ii-pioneer-de-la-therapie-genique-gs030-dans-la-retinopathie-pigmentaire/ 2026-09-24T04:09:51+00:00 https://www.gensight-biologics.com/fr/2017/10/25/gensight-biologics-nomme-barrett-katz-au-poste-de-directeur-medical/ 2026-09-24T04:09:52+00:00 https://www.gensight-biologics.com/fr/2017/10/26/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-201/ 2026-09-24T04:09:52+00:00 https://www.gensight-biologics.com/fr/2017/11/06/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-en-novembre/ 2026-09-24T04:09:52+00:00 https://www.gensight-biologics.com/fr/2017/10/02/gensight-biologics-integre-lindice-enternext-pea-pme-150/ 2026-09-24T04:09:53+00:00 https://www.gensight-biologics.com/fr/2017/10/04/gensight-biologics-invitee-a-presenter-a-la-chardan-gene-therapy-conference-a-new-york/ 2026-09-24T04:09:53+00:00 https://www.gensight-biologics.com/fr/2017/10/16/gensight-biologics-presente-des-resultats-de-gs010-et-gs030-au-congres-2017-de-la-european-society-of-gene-cell-therapy/ 2026-09-24T04:09:53+00:00 https://www.gensight-biologics.com/fr/2017/07/28/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2017/ 2026-09-24T04:09:54+00:00 https://www.gensight-biologics.com/fr/2017/08/01/gensight-biologics-annonce-la-fin-du-recrutement-de-son-etude-de-phase-iii-rescue-avec-gs010-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber/ 2026-09-24T04:09:54+00:00 https://www.gensight-biologics.com/fr/2017/09/19/gensight-biologics-integre-les-indices-cac-small-cac-mid-and-small-et-cac-all-tradable-deuronext/ 2026-09-24T04:09:54+00:00 https://www.gensight-biologics.com/fr/2017/06/23/gensight-biologics-leve-avec-succes-225-me-aupres-dinvestisseurs-americains-et-europeens/ 2026-09-24T04:09:55+00:00 https://www.gensight-biologics.com/fr/2017/06/23/mise-a-disposition-du-public-de-la-note-doperation-ayant-obtenu-le-visa-n-17-297-de-lamf-dans-le-cadre-de-laugmentation-de-capital-de-gensight-biologics/ 2026-09-24T04:09:55+00:00 https://www.gensight-biologics.com/fr/2017/05/08/gensight-biologics-presente-des-resultats-de-gs010-et-gs030-au-congres-2017-de-larvo/ 2026-09-24T04:09:56+00:00 https://www.gensight-biologics.com/fr/2017/06/14/gensight-biologics-annonce-des-resultats-positifs-de-securite-et-dacuite-visuelle-a-96-semaines-de-son-etude-de-phase-i-ii-avec-gs010-pour-le-traitement-de-la-neuropathie-optique-hereditai/ 2026-09-24T04:09:56+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/gensight-biologics-cp-96-weeks-results_vdef.jpg https://www.gensight-biologics.com/wp-content/uploads/2017/06/gensight-biologics-cp-96-weeks-results_vdef.jpg https://www.gensight-biologics.com/fr/2017/06/22/gensight-biologics-lance-une-augmentation-de-capital-denviron-20me/ 2026-09-24T04:09:56+00:00 https://www.gensight-biologics.com/fr/2017/04/28/gensight-biologics-met-a-disposition-son-document-de-reference-2016/ 2026-09-24T04:09:57+00:00 https://www.gensight-biologics.com/fr/2017/05/03/gensight-biologics-nomme-mohamed-genead-au-poste-de-directeur-medical/ 2026-09-24T04:09:57+00:00 https://www.gensight-biologics.com/fr/2017/05/03/gensight-biologics-nomme-mohamed-genead-au-poste-de-directeur-medical-2/ 2026-09-24T04:09:57+00:00 https://www.gensight-biologics.com/fr/2017/04/20/gensight-biologics-presente-gs010-au-congres-annuel-2017-de-lamerican-academy-of-neurology/ 2026-09-24T04:09:58+00:00 https://www.gensight-biologics.com/fr/2017/04/27/gensight-biologics-presente-gs010-au-4eme-annual-retinal-cell-gene-therapy-innovation-summit/ 2026-09-24T04:09:58+00:00 https://www.gensight-biologics.com/fr/2017/03/13/gensight-biologics-publie-ses-resultats-financiers-2016/ 2026-09-24T04:09:59+00:00 https://www.gensight-biologics.com/fr/2017/03/28/gensight-biologics-presente-des-resultats-de-gs010-au-congres-2017-du-nanos/ 2026-09-24T04:09:59+00:00 https://www.gensight-biologics.com/fr/2017/04/19/gensight-biologics-invitee-a-presenter-lors-de-prochaines-conferences-investisseurs/ 2026-09-24T04:09:59+00:00 https://www.gensight-biologics.com/fr/2016/12/20/gensight-biologics-annonce-un-gain-dacuite-visuelle-a-78-semaines-de-suivi-dans-son-etude-de-phase-i-ii-avec-gs010-pour-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber-nohl/ 2026-09-24T04:10:00+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/gensight-biologics-cp-78-weeks-results_vfinal.jpg https://www.gensight-biologics.com/wp-content/uploads/2016/12/gensight-biologics-cp-78-weeks-results_vfinal.jpg https://www.gensight-biologics.com/fr/2017/01/31/gensight-biologics-obtient-la-designation-de-medicament-orphelin-aux-etats-unis-pour-gs030-dans-la-retinopathie-pigmentaire/ 2026-09-24T04:10:00+00:00 https://www.gensight-biologics.com/fr/2017/02/22/gensight-biologics-annonce-la-fin-du-recrutement-de-son-etude-de-phase-iii-reverse-avec-gs010-dans-le-traitement-de-la-neuropathie-optique-hereditaire-de-leber/ 2026-09-24T04:10:00+00:00 https://www.gensight-biologics.com/fr/2016/09/08/gensight-biologics-obtient-lautorisation-dinclure-des-adolescents-dans-les-etudes-cliniques-de-phase-iii-rescue-et-reverse-avec-gs010-dans-la-neuropathie-optique-hereditaire-de-leb/ 2026-09-24T04:10:01+00:00 https://www.gensight-biologics.com/fr/2016/10/13/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2016/ 2026-09-24T04:10:01+00:00 https://www.gensight-biologics.com/fr/2016/05/26/gensight-biologics-annonce-lenregistrement-de-son-document-de-base-dans-le-cadre-de-son-projet-dintroduction-en-bourse-sur-le-marche-reglemente-deuronext-a-paris/ 2026-09-24T04:10:02+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/1464157504_gensight-biologics-enregistrement-ddb_fr_20160525.jpg https://www.gensight-biologics.com/wp-content/uploads/2016/05/1464157504_gensight-biologics-enregistrement-ddb_fr_20160525.jpg https://www.gensight-biologics.com/fr/2016/07/05/gensight-biologics-lance-son-introduction-en-bourse-sur-le-marche-reglemente-deuronext-paris/ 2026-09-24T04:10:02+00:00 https://www.gensight-biologics.com/fr/2016/07/13/gensight-biologics-annonce-le-succes-de-son-introduction-en-bourse-sur-euronext-paris/ 2026-09-24T04:10:02+00:00 https://www.gensight-biologics.com/fr/2016/08/11/gensight-biologics-confirme-le-succes-de-son-introduction-en-bourse-en-exercant-loption-de-surallocation-a-889/ 2026-09-24T04:10:02+00:00 https://www.gensight-biologics.com/fr/2016/08/11/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie/ 2026-09-24T04:10:02+00:00 https://www.gensight-biologics.com/fr/2016/09/01/gensight-biologics-obtient-la-designation-de-medicament-orphelin-et-la-classification-de-medicament-de-therapie-innovante-en-europe-pour-gs030-dans-la-retinopathie-pigmentaire/ 2026-09-24T04:10:02+00:00 https://www.gensight-biologics.com/fr/2019/01/23/arvo-conference-annuelle-vancouver-bc-canada/ 2026-10-26T02:20:45+00:00 https://www.gensight-biologics.com/2019/02/04/gensight-biologics-reports-topline-results-at-week-48-of-the-rescue-phase-iii-clinical-trial-of-gs010-in-subjects-within-six-months-of-visual-loss-onset-due-to-leber-hereditary-optic-neuropathy-lhon/ 2026-10-26T02:20:45+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-1_VA-Rescue-e1549226108277.png https://www.gensight-biologics.com/wp-content/uploads/2019/02/Image-1_VA-Rescue-e1549226108277.png https://www.gensight-biologics.com/wp-content/uploads/2019/02/Image-2_VA-Rescue-Reverse.png https://www.gensight-biologics.com/fr/2019/03/19/sonoma-eye-2019-sonoma-ca/ 2026-10-26T02:20:47+00:00 https://www.gensight-biologics.com/fr/2019/06/25/umdf-mitochondrial-medicine-2019-washington-dc-us/ 2026-10-26T02:20:55+00:00 https://www.gensight-biologics.com/fr/2019/09/19/american-academy-of-ophthalmology-san-francisco-ca/ 2026-10-26T02:20:57+00:00 https://www.gensight-biologics.com/fr/2019/09/19/ophthalmology-innovation-summit-aao-san-francisco-ca/ 2026-10-26T02:20:58+00:00 https://www.gensight-biologics.com/fr/2019/09/23/future-is-now-leaders-in-ocular-gene-therapy-meeting-san-francisco-ca/ 2026-10-26T02:20:59+00:00 https://www.gensight-biologics.com/fr/2019/10/14/ever-2019-nice-fr/ 2026-10-26T02:21:02+00:00 https://www.gensight-biologics.com/fr/2019/11/21/38th-annual-j-p-morgan-healthcare-conference-san-francisco-ca-usa/ 2026-10-26T02:21:03+00:00 https://www.gensight-biologics.com/2020/01/20/gensight-biologics-announces-its-2020-financial-calendar/ 2026-10-26T02:21:05+00:00 https://www.gensight-biologics.com/2020/01/21/gensight-biologics-reports-its-cash-position-as-of-december-31-2019-and-provides-operational-update/ 2026-10-26T02:21:06+00:00 https://www.gensight-biologics.com/fr/2020/02/04/46th-nanos-annual-meeting-amelia-island-florida-us/ 2026-10-26T02:21:06+00:00 https://www.gensight-biologics.com/fr/2020/02/04/bio-europe-spring-paris-france/ 2026-10-26T02:21:06+00:00 https://www.gensight-biologics.com/2020/02/04/2020-cell-gene-meeting-on-the-mediterranean-barcelona-spain/ 2026-10-26T02:21:07+00:00 https://www.gensight-biologics.com/2020/03/03/gensight-biologics-announces-presentation-of-bilateral-visual-recovery-from-gs010-lumevoq-phase-iii-trials-at-the-46th-annual-meeting-of-nanos/ 2026-10-26T02:21:07+00:00 https://www.gensight-biologics.com/2020/03/12/gensight-biologics-reports-full-year-2019-financial-results-and-provides-an-outlook-on-2020/ 2026-10-26T02:21:08+00:00 https://www.gensight-biologics.com/2020/04/06/gensight-biologics-provides-update-on-operations-in-the-context-of-covid-19/ 2026-10-26T02:21:08+00:00 https://www.gensight-biologics.com/2020/04/08/gensight-biologics-announces-the-filing-of-its-2019-universal-registration-document/ 2026-10-26T02:21:08+00:00 https://www.gensight-biologics.com/2020/04/08/annual-general-meeting-on-april-29-2020-procedures-for-obtaining-preparatory-documents-for-the-general-meeting/ 2026-10-26T02:21:08+00:00 https://www.gensight-biologics.com/2020/04/09/h-c-wainwright-global-life-sciences-conference-cancelled/ 2026-10-26T02:21:09+00:00 https://www.gensight-biologics.com/2020/04/14/gensight-biologics-announces-positive-data-safety-monitoring-board-review-of-pioneer-phase-i-ii-trial-of-gs030-combining-gene-therapy-and-optogenetics-for-the-treatment-of-retinitis-pigmentosa/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/04/15/gensight-biologics-on-track-to-submit-lumevoq-for-european-approval-in-september-2020-following-pre-submission-meeting-with-ema/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/04/21/gensight-biologics-reports-cash-position-as-of-march-31-2020-and-provides-operational-update/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/04/22/2020-aan-annual-meeting-toronto-canada-canceled-due-to-covid-19/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/04/22/gensight-biologics-will-hold-its-general-meeting-on-april-29-2020-behind-closed-doors/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/04/29/asgct-23rd-annual-meeting-boston-ma-usa-virtual-format/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/05/19/2020-arvo-annual-meeting-baltimore-md-us-cancelled/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/05/19/bio-2020-san-diego-ca-us-digital/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/06/24/kol-call-on-lumevoq-for-the-treatment-of-leber-hereditary-optic-neuropathy-lhon/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Nancy-Newman.jpg https://www.gensight-biologics.com/2020/07/02/gensight-biologics-to-host-lumevoq-key-opinion-leader-call-on-july-9-2020/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/07/06/gensight-biologics-reports-sustained-efficacy-and-safety-among-lhon-patients-three-years-after-lumevoq-treatment/ 2026-10-26T02:21:10+00:00 https://www.gensight-biologics.com/2020/07/09/gensight-biologics-obtains-a-e7m-non-dilutive-loan-and-renegotiates-the-bond-agreement-with-kreos-capital-extending-runway-to-mid-2021/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/2020/07/21/gensight-biologics-reports-final-reality-natural-history-study-results-confirming-poor-spontaneous-recovery-for-lhon-patients-with-nd4-mutation/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph_Reality-full.png https://www.gensight-biologics.com/2020/07/30/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2020-and-provides-operational-update/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/2020/07/30/2020-annual-scientific-meeting-asrs-virtual-format/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/2020/07/30/umdf-power-surge-2020-online-event/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/2020/08/04/gensight-biologics-draws-down-the-e4-million-second-tranche-of-bonds-from-kreos-capital/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/fr/2020/09/04/ois-retina-innovation-showcase/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/2020/09/14/h-c-wainwright-22nd-annual-global-investment-conference-virtual-conference/ 2026-10-26T02:21:11+00:00 https://www.gensight-biologics.com/2020/09/15/gensight-biologics-submits-eu-marketing-authorisation-application-for-lumevoq-gene-therapy-to-treat-vision-loss-due-to-leber-hereditary-optic-neuropathy-lhon/ 2026-10-26T02:21:12+00:00 https://www.gensight-biologics.com/2020/09/21/gensight-biologics-reports-new-analysis-demonstrating-statistically-significant-and-clinically-meaningful-difference-between-visual-outcomes-in-lumevoq-treated-patients-and-natural-history-of-le/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/image-graph.png https://www.gensight-biologics.com/wp-content/uploads/2020/09/image-graph.png https://www.gensight-biologics.com/2020/09/28/gensight-biologics-announces-publication-of-meta-analysis-confirming-that-spontaneous-recovery-in-lhon-is-rare-in-the-journal-of-neuro-ophthalmology/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/01/chardan-4th-annual-genetic-medicines-conference-virtual/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/01/ophthalmology-futures-retina-virtual-forum/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/01/healthtech-innovation-days-htid-paris-france-virtual-conference/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/01/euretina-2020-virtual/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/05/cell-gene-meeting-on-the-mesa-virtual/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/14/gensight-biologics-appoints-elsy-boglioli-to-its-board-of-directors/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/15/gensight-biologics-reports-cash-position-as-of-september-30-2020-and-provides-operational-update/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/19/4th-annual-gene-therapy-for-rare-disorders-europe-virtual/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/fr/2020/10/19/bioeurope-digital/ 2026-10-26T02:21:13+00:00 https://www.gensight-biologics.com/2020/10/21/gensight-biologics-launches-a-capital-increase-of-approximately-e25-million-by-means-of-an-accelerated-bookbuilding-process-2/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/2020/10/22/gensight-biologics-successfully-raises-e25-million-in-an-oversubscribed-private-placement-with-us-and-european-institutional-investors/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/2020/11/02/eyecelerator-2020-virtual-conference/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/fr/2020/11/02/world-orphan-drug-congress-europe-2020-live-digital/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/2020/11/03/gensight-biologics-reports-validation-of-lumevoq-marketing-authorisation-application-maa-by-european-medicines-agency/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/2020/11/12/american-academy-of-ophthalmology-2020-virtual/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/2020/11/13/bryan-garnier-european-healthcare-conference-2020-virtual-event/ 2026-10-26T02:21:14+00:00 https://www.gensight-biologics.com/2020/12/10/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-iii-trial-and-non-human-primate-study-in-science-translational-medicine/ 2026-10-26T02:21:15+00:00 https://www.gensight-biologics.com/2020/12/10/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital/ 2026-10-26T02:21:15+00:00 https://www.gensight-biologics.com/2021/01/07/39th-annual-j-p-morgan-healthcare-conference-virtual/ 2026-10-26T02:21:15+00:00 https://www.gensight-biologics.com/2021/01/07/47th-nanos-annual-meeting-virtual-meeting/ 2026-10-26T02:21:15+00:00 https://www.gensight-biologics.com/2021/01/13/gensight-biologics-announces-publication-of-results-from-lumevoq-rescue-pivotal-phase-iii-trial-in-aao-journal-ophthalmology/ 2026-10-26T02:21:15+00:00 https://www.gensight-biologics.com/2021/01/18/gensight-biologics-announces-its-2021-financial-calendar/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/01/19/gensight-biologics-reports-cash-position-as-of-december-31-2020-and-provides-operational-update/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/02/04/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-non-human-primates/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/02/05/44th-annual-macula-society-meeting-virtual/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/02/12/ois-gene-therapy-innovation-showcase-virtual/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/02/12/4th-annual-gene-therapy-for-rare-disorders-virtual/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/02/15/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-i-iia-clinical-trial-reveal-in-biodrugs/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/03/08/ophthalmology-future-forums-asian-retina-virtual-forum-march-25-2021/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/03/08/cell-gene-meeting-on-the-mediterranean-virtual/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/03/08/2021-aan-annual-meeting-virtual/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/03/10/gensight-biologics-reports-full-year-2020-financial-results-and-provides-an-outlook-on-2021/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/03/15/bioeurope-spring-virtual/ 2026-10-26T02:21:16+00:00 https://www.gensight-biologics.com/2021/03/25/gensight-biologics-launches-a-reserved-offering-of-c-e25-million-by-means-of-an-accelerated-bookbuilding-process/ 2026-10-26T02:21:17+00:00 https://www.gensight-biologics.com/2021/03/26/gensight-biologics-successfully-raises-e30-million-in-an-oversubscribed-private-placement-with-european-and-us-institutional-investors/ 2026-10-26T02:21:17+00:00 https://www.gensight-biologics.com/2021/04/08/annual-general-meeting-on-april-29-2021/ 2026-10-26T02:21:17+00:00 https://www.gensight-biologics.com/2021/04/08/gensight-biologics-announces-the-filing-of-its-2020-universal-registration-document/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/04/19/mitochondria-targeted-drug-development-summit-digital/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/04/20/gensight-biologics-reports-cash-position-as-of-march-31-2021-and-provides-operational-update/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/04/20/2021-arvo-annual-meeting-virtual/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/04/27/annual-general-meeting-2021/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/05/03/gensight-biologics-announces-publication-of-results-from-the-reality-lhon-natural-history-study-in-the-journal-eye/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-graph-Reality-Paper.png https://www.gensight-biologics.com/wp-content/uploads/2021/05/Image-graph-Reality-Paper.png https://www.gensight-biologics.com/2021/05/14/gensight-biologics-provides-2021-operations-update-in-the-context-of-covid-19/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/05/17/gensight-biologics-appoints-francoise-de-craecker-to-its-board-of-directors/ 2026-10-26T02:21:18+00:00 https://www.gensight-biologics.com/2021/05/18/advanced-therapies-virtual/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/05/19/gensight-biologics-appoints-country-leads-for-france-germany-and-the-uk-in-preparations-for-lumevoq-commercial-launch/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/05/28/kol-webinar-on-the-nature-medicine-case-report-visual-recovery-after-gs030-optogenetic-treatment/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/05/31/gensight-biologics-to-host-a-key-opinion-leader-webinar-on-the-nature-medicine-case-report-visual-recovery-after-gs030-optogenetic-treatment/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/06/01/gensight-biologics-announces-publication-of-indirect-comparison-showing-treatment-effect-of-lumevoq-versus-natural-history-in-frontiers-in-neurology/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Image-graph-Ind-Comp-LHOn-May-2021.png https://www.gensight-biologics.com/wp-content/uploads/2021/05/Image-graph-Ind-Comp-LHOn-May-2021.png https://www.gensight-biologics.com/2021/06/08/bio-us-2021-digital/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/06/08/clinical-operations-strategy-meeting-online-2021/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/06/10/gensight-biologics-appoints-marion-ghibaudo-as-chief-technical-officer-to-lead-gs030-device-engineering/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/06/15/umdf-mitochondrial-medicine-2021-virtual/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/06/29/biotech-outsourcing-strategies-bos-2021-virtual/ 2026-10-26T02:21:19+00:00 https://www.gensight-biologics.com/2021/06/30/gensight-biologics-reports-topline-results-from-reflect-phase-iii-clinical-trial-confirming-lumevoq-efficacy-including-better-efficacy-with-bilateral-treatment/ 2026-10-26T02:21:20+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-1.jpg https://www.gensight-biologics.com/wp-content/uploads/2021/06/Graph-1.jpg https://www.gensight-biologics.com/wp-content/uploads/2021/06/Graph-2.jpg https://www.gensight-biologics.com/2021/07/05/gensight-biologics-announces-approval-of-the-lumevoq-cohort-temporary-authorization-for-use-atuc-in-france/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/07/05/gensight-biologics-to-host-key-opinion-leader-webcasts-on-the-topline-results-from-reflect-phase-iii-clinical-trial-of-lumevoq/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/07/06/kol-webcast-on-the-topline-results-from-reflect-phase-iii-clinical-trial-of-lumevoq/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/07/06/french-retail-investors-webcast/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/07/12/ois-european-innovation-showcase-virtual/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/07/29/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2021-and-provides-operational-update/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/08/31/gensight-biologics-announces-publication-of-restore-study-data-demonstrating-sustained-efficacy-3-years-after-unilateral-injection-of-lumevoq/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-restore-3y-FU-PR-31AUG2021.png https://www.gensight-biologics.com/wp-content/uploads/2021/08/Graph-restore-3y-FU-PR-31AUG2021.png https://www.gensight-biologics.com/2021/09/01/clinical-data-on-gensight-biologics-lumevoq-and-gs030-gene-therapies-to-be-presented-at-2021-isgedr-and-several-investor-and-industry-meetings-in-september/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/09/02/2021-isgedr-meeting-international-society-for-genetic-eye-diseases-retinoblastoma/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/09/02/redburn-gene-therapy-virtual-summit-2021/ 2026-10-26T02:21:21+00:00 https://www.gensight-biologics.com/2021/09/06/uk-mhra-grants-gensight-biologics-lumevoq-ophthalmic-gene-therapy-promising-innovative-medicine-designation/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/07/ophthalmology-futures-forums-euro-retina-virtual-forum-september-8-2021/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/09/gensight-biologics-announces-publication-analyzing-visual-parameters-of-nd4-lhon-subjects-before-lumevoq-treatment-in-phase-iii-trials/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/wp-content/uploads/2021/09/R-R-BSL.png https://www.gensight-biologics.com/2021/09/13/clinical-trials-in-rare-diseases-conference-2021-europe-and-usa-virtual-conference/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/13/5th-annual-cell-gene-therapy-world-asia-virtual/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/13/2nd-annual-gene-therapy-for-ophthalmic-disorders-digital-event/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/15/gensight-biologics-announces-positive-data-safety-monitoring-board-review-of-pioneer-phase-i-ii-clinical-trial-of-gs030-as-optogenetic-treatment-for-retinitis-pigmentosa/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/24/advanced-therapies-connect-online-event/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/09/24/54th-annual-scientific-meeting-of-the-retina-society-chicago-il-usa/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/10/04/clinical-data-on-gensight-biologics-lumevoq-and-gs030-gene-therapies-to-be-presented-at-2021-asrs-esgct-and-several-investor-and-industry-meetings-in-october/ 2026-10-26T02:21:22+00:00 https://www.gensight-biologics.com/2021/10/04/healthtech-innovation-days-htid-virtual/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/04/chardan-5th-annual-genetic-medicines-conference-virtual/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/04/2021-advanced-therapies-congress-live-london-uk/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/05/ois-retina-innovation-summit-asrs-austin-tx-usa/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/06/gensight-biologics-announces-the-publication-of-a-review-of-gene-therapy-trials-for-lhon-in-international-ophthalmology-clinics/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/06/39th-annual-scientific-meeting-of-the-american-society-of-retina-specialists-asrs/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/11/2021-arm-cell-gene-meeting-on-the-mesa-carlsbad-ca-usa-virtual-2/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/11/28th-annual-congress-of-the-european-society-of-gene-cell-therapy-esgct-virtual/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/11/mitochondrial-diseases-conference-2021-by-mitocon-virtual/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/12/gensight-biologics-announces-fda-grant-of-fast-track-designation-for-optogenetic-therapy-gs030-as-treatment-for-retinitis-pigmentosa/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/18/bio-europe-2021-virtual/ 2026-10-26T02:21:24+00:00 https://www.gensight-biologics.com/2021/10/18/cell-uk-by-oxfords-global-london-uk-virtual/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/11/04/gensight-biologics-provides-update-on-manufacturing-timeline-needed-for-lumevoq-regulatory-filing/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/11/10/gensight-biologics-reports-cash-position-as-of-september-30-2021-and-provides-operational-update/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/11/12/gensight-biologics-to-present-new-clinical-data-of-lumevoq-and-gs030-gene-therapies-at-the-american-academy-of-ophthalmology-2021-meeting/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/11/15/gensight-biologics-announces-extension-of-day-120-clock-stop-of-lumevoq-ema-regulatory-filing-maa-review-to-resume-in-april-2022/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/11/17/gensight-biologics-reports-second-patient-case-showing-significant-visual-recovery-after-gs030-optogenetic-treatment/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/11/30/gensight-biologics-to-host-key-opinion-leader-webcast-on-outcomes-among-compassionate-use-patients-treated-bilaterally-with-lumevoq-in-the-us/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/12/01/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/ 2026-10-26T02:21:25+00:00 https://www.gensight-biologics.com/2021/12/14/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-2-year-follow-up-of-reflect-phase-iii-trial/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/REFLECT-Year-2-BCVA-from-baseline.png https://www.gensight-biologics.com/2022/01/18/gensight-biologics-reports-cash-position-as-of-december-31-2021-and-provides-operational-update/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/2022/01/24/gensight-biologics-reports-clinically-meaningful-vision-improvement-is-maintained-4-years-after-one-time-treatment-with-lumevoq-gene-therapy/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/LOESS-curves-RESTORE-Year-4.jpg https://www.gensight-biologics.com/2022/02/01/gensight-biologics-appoints-sissel-rodahl-as-senior-vice-president-of-commercial-operations-to-lead-the-launch-of-lumevoq-in-europe/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/2022/02/14/gensight-biologics-to-present-reflect-phase-iii-data-with-lumevoq-at-the-nanos-2022-meeting/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/2022/03/11/gensight-biologics-announces-its-2022-financial-calendar/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/2022/04/07/gensight-biologics-provides-update-on-lumevoq-manufacturing-timeline/ 2026-10-26T02:21:41+00:00 https://www.gensight-biologics.com/2022/04/08/gensight-biologics-reports-full-year-2021-consolidated-financial-results/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/04/14/gensight-biologics-granted-six-month-extension-in-lumevoq-european-regulatory-review/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/04/21/gensight-biologics-reports-cash-position-and-revenues-as-of-march-31-2022/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/04/29/gensight-biologics-announces-the-filing-of-its-2021-universal-registration-document/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/05/04/annual-general-meeting-on-may-25-2022-procedures-for-obtaining-preparatory-documents-for-the-general-meeting/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/05/19/gensight-biologics-announces-publication-of-a-study-of-the-impact-of-lhon-disease-on-the-lives-of-patients-and-relatives-in-journal-of-neuro-ophthalmology/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/06/16/gensight-biologics-announces-participation-and-presentation-of-gs010-clinical-data-at-eunos-2022/ 2026-10-26T02:21:42+00:00 https://www.gensight-biologics.com/2022/07/28/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2022/ 2026-10-26T02:21:43+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/resultats-intermediaires.jpg https://www.gensight-biologics.com/2022/09/12/gensight-biologics-strengthens-its-management-team-to-support-the-launch-of-lumevoq-in-europe/ 2026-10-26T02:21:43+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Philippe-Motte-e1662963007510.png https://www.gensight-biologics.com/2022/09/19/gensight-biologics-announces-successful-completion-of-lumevoq-engineering-batch-validating-implemented-corrective-actions/ 2026-10-26T02:21:43+00:00 https://www.gensight-biologics.com/2022/09/20/gensight-biologics-to-present-at-upcoming-industry-and-investor-conferences/ 2026-10-26T02:21:43+00:00 https://www.gensight-biologics.com/2022/09/29/gensight-biologics-to-present-at-upcoming-2022-medical-conferences/ 2026-10-26T02:22:05+00:00 https://www.gensight-biologics.com/2022/10/28/gensight-biologics-reports-cash-position-and-revenues-as-of-september-30-2022/ 2026-10-26T02:22:05+00:00 https://www.gensight-biologics.com/2022/11/17/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial-in-peer-reviewed-journals/ 2026-10-26T02:22:05+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Figure-1-REFLECT-TITRE.jpg https://www.gensight-biologics.com/2022/12/15/gensight-biologics-announces-publication-of-indirect-comparison-of-lumevoq-versus-natural-history-in-nd4-lhon-patients-in-peer-reviewed-journal-ophthalmology-and-therapy/ 2026-10-26T02:22:05+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Figure-1.jpg https://www.gensight-biologics.com/2022/12/23/gensight-biologics-secures-e12-million-financing-through-a-premium-convertible-notes-issuance-to-an-institutional-investor-and-provides-business-update/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/01/04/gensight-biologics-to-present-at-upcoming-investor-conferences/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/01/26/10102/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/02/06/gensight-biologics-announces-the-drawdown-of-the-first-eur-8-million-tranche-under-its-credit-agreement-with-the-european-investment-bank/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/02/13/gensight-biologics-announces-1-year-safety-data-and-efficacy-signals-from-pioneer-phase-i-ii-clinical-trial-of-gs030-an-optogenetic-treatment-candidate-for-retinitis-pigmentosa/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/02/28/rare-disease-day-2023-gensight-biologics-raises-awareness-of-leber-hereditary-optic-neuropathy-lhon/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/02/28/gensight-biologics-announces-its-2023-financial-calendar/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/03/07/gensight-biologics-provides-update-on-lumevoq-manufacturing-and-commercialization-timelines/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/03/09/gensight-biologics-announces-publication-of-lumevoq-safety-data-over-5-year-period-in-renowned-peer-reviewed-american-journal-of-ophthalmology/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/03/10/gensight-biologics-to-present-at-upcoming-medical-conferences/ 2026-10-26T02:22:06+00:00 https://www.gensight-biologics.com/2023/03/13/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-3-year-follow-up-of-reflect-phase-iii-trial/ 2026-10-26T02:22:07+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-1-3.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/Graph-1-500x364.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/EN-tab-2-500x176.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/TAB-1-EN-500x274.jpg https://www.gensight-biologics.com/2023/03/15/gensight-biologics-announces-presentation-of-lumevoq-efficacy-and-safety-data-from-early-access-programs-for-nd4-lhon-patients-at-nanos-2023/ 2026-10-26T02:22:07+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph.jpg https://www.gensight-biologics.com/wp-content/uploads/2023/03/Graph-466x500.jpg https://www.gensight-biologics.com/2023/03/24/gensight-biologics-reports-full-year-2022-consolidated-financial-results/ 2026-10-26T02:22:07+00:00 https://www.gensight-biologics.com/2023/04/04/gensight-biologics-to-host-a-webcast-on-april-5-2023-to-provide-an-update-on-lumevoq-manufacturing-following-investigations-findings/ 2026-10-26T02:22:07+00:00 https://www.gensight-biologics.com/2023/04/20/gensight-biologics-withdraws-its-ema-application-for-lumevoq/ 2026-10-26T02:22:48+00:00 https://www.gensight-biologics.com/2023/04/21/gensight-biologics-reports-cash-position-as-of-march-31-2023-and-provides-business-update/ 2026-10-26T02:22:49+00:00 https://www.gensight-biologics.com/2023/05/10/gensight-biologics-announces-the-filing-of-its-2022-universal-registration-document-and-reschedules-its-annual-general-meeting-on-june-21-2023/ 2026-10-26T02:22:49+00:00 https://www.gensight-biologics.com/2023/05/31/annual-general-meeting-on-june-21-2023/ 2026-10-26T02:22:50+00:00 https://www.gensight-biologics.com/2023/07/20/gensight-biologics-provides-financial-and-operational-update/ 2026-10-26T02:22:50+00:00 https://www.gensight-biologics.com/2023/08/03/gensight-biologics-obtains-funding-of-e10-million-from-sofinnova-partners-invus-and-upmc-enterprises/ 2026-10-26T02:22:51+00:00 https://www.gensight-biologics.com/2023/09/15/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2023/ 2026-10-26T02:22:51+00:00 https://www.gensight-biologics.com/2023/09/18/gensight-biologics-announces-successful-manufacture-of-lumevoq-gmp-batch/ 2026-10-26T02:22:51+00:00 https://www.gensight-biologics.com/2023/09/27/gensight-biologics-provides-update-on-european-medicines-agency-scientific-advice-for-lumevoq/ 2026-10-26T02:22:52+00:00 https://www.gensight-biologics.com/2023/10/26/gensight-biologics-reports-cash-position-as-of-september-30-2023-and-provides-business-update/ 2026-10-26T02:22:52+00:00 https://www.gensight-biologics.com/2020/11/15/article-en/ 2026-10-26T02:22:53+00:00 https://www.gensight-biologics.com/2023/11/13/gensight-biologics-announces-preliminary-assay-indicating-successful-manufacture-of-second-lumevoq-gmp-batch/ 2026-10-26T02:22:53+00:00 https://www.gensight-biologics.com/2023/11/15/gensight-biologics-confirms-2nd-successful-gmp-batch-of-lumevoq-and-eligibility-to-draw-down-bridge-financing-2nd-tranche-of-e4-million/ 2026-10-26T02:22:54+00:00 https://www.gensight-biologics.com/2023/11/20/gensight-biologics-announces-launch-of-an-offering-for-an-indicative-amount-of-e5-million-that-has-received-subscription-commitments-from-new-and-existing-shareholders-totaling-e4-million/ 2026-10-26T02:22:54+00:00 https://www.gensight-biologics.com/2023/11/21/gensight-biologics-announces-a-successful-offering-for-an-amount-of-approximately-e4-7-million/ 2026-10-26T02:22:54+00:00 https://www.gensight-biologics.com/2023/12/22/gensight-biologics-appoints-laurence-rodriguez-as-chief-executive-officer/ 2026-10-26T02:22:55+00:00 https://www.gensight-biologics.com/2023/12/27/gensight-biologics-provides-business-and-financial-update/ 2026-10-26T02:22:56+00:00 https://www.gensight-biologics.com/2024/05/07/gensight-biologics-announces-the-availability-of-a-prospectus-in-connection-with-the-listing-of-new-shares-on-euronext-paris/ 2026-10-26T02:23:17+00:00 https://www.gensight-biologics.com/2025/01/15/gensight-biologics-announces-publication-of-5-year-outcomes-for-patients-treated-unilaterally-with-lumevoq-gene-therapy/ 2026-10-26T02:23:25+00:00 https://www.gensight-biologics.com/2024/12/24/gensight-biologics-announces-a-financing-for-an-amount-of-c-e1-5-million-from-existing-investors/ 2026-10-26T02:23:25+00:00 https://www.gensight-biologics.com/2025/01/23/gensight-biologics-reports-end-of-year-cash-position-and-provides-business-update/ 2026-10-26T02:23:26+00:00 https://www.gensight-biologics.com/2025/02/12/gensight-biologics-announces-five-year-efficacy-and-safety-results-for-lumevoq-gene-therapy-at-the-conclusion-of-the-reflect-study/ 2026-10-26T02:23:26+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/REFLECT-Year-5-FIGURE-CURVES.png https://www.gensight-biologics.com/wp-content/uploads/2025/02/REFLECT-Year-5-FIGURE-CURVES-500x375.png https://www.gensight-biologics.com/wp-content/uploads/2025/02/REFLECT-Year-5-GRAPH-TABLE-500x70.png https://www.gensight-biologics.com/2025/02/27/gensight-biologics-reports-estimated-full-year-2024-consolidated-financial-results/ 2026-10-26T02:23:27+00:00 https://www.gensight-biologics.com/2025/03/07/gensight-biologics-announces-financing-amounting-to-c-e0-9-million-from-existing-investors/ 2026-10-26T02:23:27+00:00 https://www.gensight-biologics.com/2025/04/07/gensight-biologics-reports-cash-position-as-of-march-31-2025-and-provides-business-update/ 2026-10-26T02:23:28+00:00 https://www.gensight-biologics.com/2025/03/17/gensight-biologics-announces-lumevoq-scientific-updates-at-nanos-2025/ 2026-10-26T02:23:28+00:00 https://www.gensight-biologics.com/2025/03/19/gensight-biologics-confirms-definitive-full-year-2024-consolidated-financial-results-are-in-line-with-estimates/ 2026-10-26T02:23:28+00:00 https://www.gensight-biologics.com/2025/04/08/gensight-biologics-announces-the-filing-of-its-2024-universal-registration-document/ 2026-10-26T02:23:29+00:00 https://www.gensight-biologics.com/2025/04/23/annual-general-meeting-on-may-13-2025/ 2026-10-26T02:23:29+00:00 https://www.gensight-biologics.com/2025/05/13/gensight-biologics-announces-approval-of-all-resolutions-supported-by-the-board-of-directors-at-the-combined-general-meeting-of-may-13-2025/ 2026-10-26T02:23:30+00:00 https://www.gensight-biologics.com/2025/05/13/videocast-of-the-annual-general-meeting-held-on-may-13-2025-in-paris-france/ 2026-10-26T02:23:30+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Screenshot-AGM-2025.png https://www.gensight-biologics.com/wp-content/uploads/2025/05/Screenshot-AGM-2025-500x264.png https://www.gensight-biologics.com/2025/06/12/gensight-biologics-reaches-agreement-with-ansm-for-opening-of-lumevoq-named-early-access-program-aac-in-france/ 2026-10-26T02:23:30+00:00 https://www.gensight-biologics.com/2025/06/26/gensight-biologics-announces-significant-milestone-in-new-manufacturing-partnership-with-catalent/ 2026-10-26T02:23:31+00:00 https://www.gensight-biologics.com/2025/07/01/gensight-biologics-announces-successful-completion-of-a-private-placement-of-close-to-eur-4-million/ 2026-10-26T02:23:39+00:00 https://www.gensight-biologics.com/2025/07/03/gensight-biologics-announces-the-closing-of-the-companys-c-e4-million-private-placement/ 2026-10-26T02:23:39+00:00 https://www.gensight-biologics.com/2025/07/17/gensight-biologics-announces-publication-on-predictors-of-final-visual-outcome-in-patients-treated-with-lumevoq-gene-therapy/ 2026-10-26T02:23:39+00:00 https://www.gensight-biologics.com/2025/07/08/gensight-biologics-reports-cash-position-as-of-june-30-2025/ 2026-10-26T02:23:39+00:00 https://www.gensight-biologics.com/2025/07/17/gensight-biologics-announces-an-additional-financing-amounting-to-approximately-eur-500000-from-existing-shareholder/ 2026-10-26T02:23:39+00:00 https://www.gensight-biologics.com/2025/08/28/gensight-biologics-postpones-release-of-2025-half-year-financial-results/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/09/26/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-eur-3-7-million/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/10/01/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-3-7-million/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/11/10/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-e2-million/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/11/13/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-2-million/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/12/02/gensight-biologics-announces-regulatory-approval-for-gs010-lumevoq-revise-dose-ranging-study-in-france/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/07/22/gensight-biologics-announces-the-closing-of-approximately-e500000-of-additional-financing/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/09/29/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2025/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/10/07/gensight-biologics-reports-cash-position-as-of-september-30-2025/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/10/30/gensight-biologics-announces-regulatory-authorizations-for-individual-patient-expanded-access-treatment-with-gs010-lumevoq-in-the-us/ 2026-10-26T02:23:40+00:00 https://www.gensight-biologics.com/2025/12/22/gensight-biologics-announces-the-granting-of-compassionate-use-authorization-cua-aac-for-gs010-lumevoq-in-france/ 2026-10-26T02:23:41+00:00 https://www.gensight-biologics.com/2025/12/22/gensight-biologics-announces-regulatory-authorization-for-early-access-treatment-with-gs010-lumevoq-in-israel/ 2026-10-26T02:23:41+00:00 https://www.gensight-biologics.com/2025/12/29/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-e2-9-million/ 2026-10-26T02:23:41+00:00 https://www.gensight-biologics.com/2026/01/07/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-2-9-million/ 2026-10-26T02:23:41+00:00 https://www.gensight-biologics.com/2026/01/08/gensight-biologics-reports-cash-position-as-of-december-31-2025-and-provides-business-updates/ 2026-10-26T02:23:41+00:00 https://www.gensight-biologics.com/2026/03/09/gensight-biologics-provides-updates-about-gs010-lumevoq-early-access-programs-and-the-ongoing-revise-study/ 2026-10-26T02:23:43+00:00 https://www.gensight-biologics.com/2026/03/10/gensight-biologics-announces-successful-fundraising-worth-nearly-e1-7-million/ 2026-10-26T02:23:43+00:00 https://www.gensight-biologics.com/2026/01/28/gensight-biologics-announces-the-results-of-its-extraordinary-general-meeting-of-january-28-2026/ 2026-10-26T02:23:43+00:00 https://www.gensight-biologics.com/2026/02/10/the-15-20-national-hospital-and-gensight-biologics-announce-the-treatment-of-the-first-patient-in-the-gs010-lumevoq-revise-study/ 2026-10-26T02:23:43+00:00 https://www.gensight-biologics.com/2026/02/18/gensight-biologics-bolsters-regulatory-leadership-in-us-and-europe-with-two-senior-appointments/ 2026-10-26T02:23:43+00:00 https://www.gensight-biologics.com/2026/03/20/the-15-20-national-hospital-and-gensight-biologics-announce-the-first-treatments-in-the-french-named-patient-early-access-program-aac-for-gs010-lumevoq/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/03/17/gensight-biologics-announces-the-closing-of-its-nearly-e1-7-million-fundraising/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/03/27/gensight-biologics-reports-estimated-full-year-consolidated-financial-results-for-2025/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/04/03/gensight-biologics-confirms-definitive-full-year-2025-consolidated-financial-results-are-in-line-with-estimates/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/04/07/gensight-biologics-reports-cash-position-and-revenue-from-early-access-program-as-of-march-31-2026/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/04/15/gensight-biologics-announces-the-filing-of-its-2025-universal-registration-document-2/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/04/28/gensight-biologics-announces-annual-general-meeting-to-take-place-on-may-19-2026-2/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/05/11/gensight-biologics-announces-publication-on-matching-adjusted-indirect-comparison-of-leber-hereditary-optic-neuropathy-treatments-2/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2026/05/18/gensight-biologics-to-hold-its-combined-general-meeting-on-may-19-2026/ 2026-10-26T02:23:44+00:00 https://www.gensight-biologics.com/2024/12/18/gensight-biologics-provides-update-on-regulatory-discussions-and-financial-situation/ 2026-10-26T02:28:03+00:00 https://www.gensight-biologics.com/2024/11/13/gensight-biologics-announces-submission-of-lumevoq-dossier-to-ansm-to-prepare-for-restart-of-early-access-program-in-france/ 2026-10-26T02:28:26+00:00 https://www.gensight-biologics.com/2024/11/01/pricing-offering/ 2026-10-26T02:28:33+00:00 https://www.gensight-biologics.com/2024/10/28/gensight-biologics-announces-publication-of-meta-analyses-showing-better-outcomes-for-nd4-lhon-patients-treated-with-lumevoq/ 2026-10-26T02:28:43+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Meta-Analyses-Figure-1-ENG-website.jpg https://www.gensight-biologics.com/wp-content/uploads/2024/10/Meta-Analyses-Figure-1-ENG-website-500x349.jpg https://www.gensight-biologics.com/2024/10/24/gensight-biologics-reports-cash-position-as-of-september-30-2024-and-provides-business-update/ 2026-10-26T02:28:53+00:00 https://www.gensight-biologics.com/2024/10/17/gensight-biologics-announces-lumevoq-scientific-updates-at-aao-2024/ 2026-10-26T02:29:01+00:00 https://www.gensight-biologics.com/2024/09/23/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2024-provides-business-updates/ 2026-10-26T02:29:08+00:00 https://www.gensight-biologics.com/2024/07/23/gensight-biologics-reports-cash-position-as-of-june-30-2024-and-provides-business-update/ 2026-10-26T02:29:18+00:00 https://www.gensight-biologics.com/2024/07/11/gensight-biologics-launches-newsletter-for-retail-investors/ 2026-10-26T02:29:41+00:00 https://www.gensight-biologics.com/2024/06/04/gensight-biologics-to-present-at-upcoming-medical-conferences-and-stakeholder-meetings/ 2026-10-26T02:29:42+00:00 https://www.gensight-biologics.com/2024/06/20/gensight-biologics-renegotiates-financial-obligations-and-provides-operational-updates/ 2026-10-26T02:29:42+00:00 https://www.gensight-biologics.com/2024/06/03/gensight-biologics-appoints-william-monteith-to-its-board-of-directors/ 2026-10-26T02:29:42+00:00 https://www.gensight-biologics.com/2024/05/07/gensight-biologics-announces-the-availability-of-a-prospectus-in-connection-with-the-listing-of-new-shares-on-euronext-paris-2/ 2026-10-26T02:29:43+00:00 https://www.gensight-biologics.com/2024/05/30/gensight-biologics-announces-the-approval-of-all-resolutions-supported-by-the-board-of-directors-at-its-combined-general-meeting/ 2026-10-26T02:29:43+00:00 https://www.gensight-biologics.com/2024/05/07/annual-general-meeting-on-may-29-2024/ 2026-10-26T02:30:52+00:00 https://www.gensight-biologics.com/2024/04/04/gensight-biologics-announces-its-2024-financial-calendar/ 2026-10-26T02:30:53+00:00 https://www.gensight-biologics.com/2024/04/04/gensight-biologics-reports-cash-position-as-of-march-31-2024-and-provides-business-update/ 2026-10-26T02:30:53+00:00 https://www.gensight-biologics.com/2024/05/07/gensight-biologics-announces-a-successful-offering-for-an-amount-over-e9-2-million/ 2026-10-26T02:30:53+00:00 https://www.gensight-biologics.com/2024/03/06/gensight-biologics-announces-update-on-real-world-data-from-early-access-programs-of-lumevoq%ef%83%92-gene-therapy-at-nanos-2024/ 2026-10-26T02:30:54+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/BCVA-Early-Access-PR-2024-2.png https://www.gensight-biologics.com/wp-content/uploads/2024/03/BCVA-Early-Access-PR-2024-2-500x431.png https://www.gensight-biologics.com/2024/03/12/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/ 2026-10-26T02:30:54+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Figure-1-ENG-for-website.png https://www.gensight-biologics.com/wp-content/uploads/2024/03/Figure-1-ENG-for-website-500x203.png https://www.gensight-biologics.com/2024/03/20/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-four-years-after-one-time-administration/ 2026-10-26T02:30:54+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Graph-1-BCVA-Over-Time.jpg https://www.gensight-biologics.com/wp-content/uploads/2024/03/Graph-1-BCVA-Over-Time-500x331.jpg https://www.gensight-biologics.com/wp-content/uploads/2024/03/Table-1-BCVA-vs-nadir-EN-500x297.jpg https://www.gensight-biologics.com/2024/02/08/gensight-biologics-announces-completion-of-a-e5-million-capital-increase-with-sofinnova-partners-invus-upmc-enterprises-and-heights-capital/ 2026-10-26T02:30:55+00:00 https://www.gensight-biologics.com/wp-content/uploads/2026/07/Table-PR.png https://www.gensight-biologics.com/wp-content/uploads/2024/02/Table-PR-500x226.png https://www.gensight-biologics.com/2024/03/04/gensight-biologics-announces-lumevoq-scientific-updates-at-nanos-2024/ 2026-10-26T02:30:55+00:00 https://www.gensight-biologics.com/2024/04/17/gensight-biologics-announces-the-filing-of-its-2023-universal-registration-document/ 2026-10-26T02:31:21+00:00 https://www.gensight-biologics.com/2024/01/16/laurence-rodriguez-appointed-ceo-of-gensight-biologics-in-december-2023-joins-the-companys-board-of-directors/ 2026-10-26T02:31:22+00:00 https://www.gensight-biologics.com/2024/01/25/gensight-biologics-reports-cash-position-as-of-december-31-2023-and-provides-business-update/ 2026-10-26T02:31:22+00:00 https://www.gensight-biologics.com/2024/03/22/gensight-biologics-reports-full-year-2023-consolidated-financial-results/ 2026-10-26T02:31:22+00:00 https://www.gensight-biologics.com/2020/09/04/ois-retina-innovation-showcase/ 2026-10-26T02:32:16+00:00 https://www.gensight-biologics.com/2020/10/19/bioeurope-digital/ 2026-10-26T02:32:36+00:00 https://www.gensight-biologics.com/2020/11/02/world-orphan-drug-congress-europe-2020-live-digital/ 2026-10-26T02:32:55+00:00 https://www.gensight-biologics.com/2020/02/04/46th-nanos-annual-meeting-amelia-island-florida-us/ 2026-10-26T02:35:15+00:00 https://www.gensight-biologics.com/2020/02/04/bio-europe-spring-paris-france/ 2026-10-26T02:35:35+00:00 https://www.gensight-biologics.com/fr/2026/10/16/gensight-biologics-annonce-le-reglement-livraison-de-sa-levee-de-fonds-de-10-million-deuros-soutenue-par-ses-actionnaires-existants/ 2026-10-29T03:21:08+00:00 https://www.gensight-biologics.com/2026/10/16/gensight-biologics-announces-the-closing-of-its-e1-0-million-fundraising-supported-by-existing-shareholders/ 2026-10-29T03:27:17+00:00 https://www.gensight-biologics.com/fr/2026/10/08/gensight-biologics-realise-avec-succes-une-levee-de-fonds-de-10-million-deuros-soutenue-par-ses-actionnaires-existants/ 2026-10-29T16:41:43+00:00 https://www.gensight-biologics.com/2026/10/08/gensight-biologics-announces-a-successful-e1-0-million-fundraising-supported-by-existing-shareholders/ 2026-10-29T16:41:54+00:00 https://www.gensight-biologics.com/2026/10/08/gensight-biologics-and-the-15-20-national-hospital-announce-nejm-publication-on-gs030-phase-1-2-trial-results-in-late-stage-retinitis-pigmentosa/ 2026-10-29T16:42:44+00:00 https://www.gensight-biologics.com/fr/2026/10/08/gensight-biologics-et-lhopital-national-des-15-20-annoncent-la-publication-dans-le-nejm-des-resultats-de-lessai-de-phase-1-2-evaluant-gs030-dans-la-retinopathie-pigmentaire-au-stade/ 2026-10-29T16:43:14+00:00 https://www.gensight-biologics.com/2026/10/07/gensight-biologics-reports-cash-position-as-of-september-30-2026/ 2026-10-29T16:43:41+00:00 https://www.gensight-biologics.com/fr/2026/10/07/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2026/ 2026-10-29T16:43:55+00:00 https://www.gensight-biologics.com/2026/09/29/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2026-and-provides-business-updates/ 2026-10-29T16:44:25+00:00 https://www.gensight-biologics.com/fr/2026/09/29/gensight-biologics-publie-ses-resultats-financiers-du-premier-semestre-2026-et-fait-un-point-sur-son-activite/ 2026-10-29T16:44:40+00:00 https://www.gensight-biologics.com/2026/09/08/gensight-biologics-provides-september-2026-business-updates/ 2026-10-29T16:45:10+00:00 https://www.gensight-biologics.com/fr/2026/09/08/gensight-biologics-provides-september-2026-business-updates/ 2026-10-29T16:45:19+00:00 https://www.gensight-biologics.com/2026/07/08/gensight-biologics-reports-cash-position-as-of-june-30-2026-and-provides-business-updates/ 2026-10-29T16:45:56+00:00 https://www.gensight-biologics.com/fr/2026/07/08/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-juin-2026-et-fait-un-point-sur-son-activite/ 2026-10-29T16:46:02+00:00 https://www.gensight-biologics.com/2026/05/20/gensight-biologics-announces-the-results-of-its-combined-general-meeting-of-may-19-2026/ 2026-10-29T18:51:49+00:00 https://www.gensight-biologics.com/2021/05/25/gensight-biologics-announces-nature-medicine-case-report-showing-visual-recovery-after-gs030-optogenetic-treatment/ 2026-10-29T18:52:54+00:00 https://www.gensight-biologics.com/fr/2026/05/20/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026/ 2026-10-29T18:54:32+00:00